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Summary 
Objectives:
This thesis explores different symptom profiles found in First Episode Psychosis (FEP)
patients assessed at several points of time over a ten year period. Earlier studies have
focused predominantly on groups of symptoms rather than individual symptoms when 
describing course of illness and outcome, and long-term studies of symptom 
development in epidemiological FEP samples assessed multiples times are lacking. By 
studying individual symptoms longitudinally from the onset of illness we aimed to gain 
more knowledge about symptom development and the relationship between symptoms 
and outcome variables that are known to be affected in psychotic disorders. The aim of 
the study was threefold: 1) to identify a group of patients with delusions only and a group 
with hallucinations only, and examine if the groups differed with regard to 
demographics, clinical variables and outcome measures, and in particular suicidality, 2) 
to assess the prevalence of apathy ten years after the first psychotic episode, and to 
explore the association between apathy and general functioning, and between apathy and 
quality of life, and 3) to identify different flat affect (FA) symptom profiles based on 
longitudinal symptom trajectories and assess the prevalence and correlates of these 
trajectories, to assess predictors of enduring FA, and to explore the longitudinal
relationship between FA and social functioning.
Methods:
Three-hundred-and-one first episode, non organic psychosis patients were included in the 
TIPS Study (Early Treatment and Intervention in Psychosis) and followed over a ten year 
period. Patients were assessed at baseline, three months, and one, two, five and ten year 
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follow-up with an extensive battery of instruments including measures of demographics, 
duration of untreated psychosis (DUP), premorbid function (PAS), diagnosis (SCID), 
symptom measures (PANSS, AES, CDSS), measures of functioning (GAF, SCLFS), 
suicidality and quality of life (L-QoLI). The relationship of the symptoms of interest,
namely hallucinations and delusions (PANSS P1 and P3, respectively), apathy (AES-S-
Apathy and PANSS N2+N4) and flat affect (PANSS N1), to the above measures were 
assessed with t-test, correlation and regression analyses.
Results: 
Sub-groups of patients with hallucinations only and delusions only can be identified in a
five year follow-up study, and the groups differed on multiple variables. Most 
importantly, the hallucination only group scored higher on measures of suicidality, and 
insight might be a possible mediator of suicidality in this group.
Apathy was found to be a common symptom ten years after the first psychotic episode, 
affecting 30 % of the sample. Proxy-measures of apathy indicated that this symptom 
declined in the follow-up period. Clinical apathy was strongly related to poorer
functioning and to poorer subjective quality of life in patients ten years after the first 
psychotic episode. 
Five different FA trajectory groups were identified. FA was more fluctuant than 
expected, and only 5 % of the sample experienced enduring FA. Furthermore, FA was 
related to poorer functional outcome measures, in particular to objective social 
functioning, both premorbidly and throughout the ten year follow-up period.
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Conclusions:
By looking at individual symptoms rather than groups of symptoms it was possible to 
shed light on patients with symptom profiles that previously have received limited 
attention, and to learn more about the long-term development of the individual 
symptoms. Combined, the findings highlight the importance of looking at symptoms 
separately in order to both better understand the longitudinal association between 
symptoms, and to gain knowledge of how individual symptom profiles affect outcome 
measures including suicidality, quality of life, and social functioning.
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1. Introduction
1.1 Psychosis and psychotic disorders
The term “psychosis” was coined in 1841 by the German physician Karl Friedrich 
Canstatt, from the Greek "psyche", meaning mind/soul, and "-osis", meaning abnormal 
condition (Canstatt, 1841). Several definitions of psychosis exists, uniting them is a loss 
of contact with reality and reality distorting phenomena like hallucinations and delusions. 
Broader definitions include disordered thought and emotion that influences functioning.
The term psychosis came to substitute and formalize the older term “insanity”, and 
separated the more serious conditions of the mind from the milder “neurosis”. Another 
German physician, Emil Kraepelin, divided psychosis into manic depressive insanity
(now bipolar disorder, an affective psychosis) and dementia praecox (now schizophrenia,
a non-affective psychosis) (Kraepelin, 1919). In his description of dementia praecox he 
focused not only on hallucinations and delusions, symptoms we now refer to as “positive 
symptoms” of psychotic illness, he also described “...emotional dullness...loss of mastery 
over volition, of endeavor, and of ability for independent action”, similar to apathy or 
amotivation that we now group as a negative symptom of psychotic illness.
Positive psychotic symptoms, like hallucinations and delusions, and also negative 
symptoms, like apathy and flat affect (FA), occur in a variety of neuropsychiatric 
conditions and as a consequence of substance abuse and as side-effects of prescribed 
medication. The focus of this thesis is on patients with non-affective psychotic disorders 
and affective psychotic disorders with mood incongruent psychotic symptoms followed 
from their first psychotic episode. The most studied psychotic illness is schizophrenia.
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1.1.1 Schizophrenia
Schizophrenia is regarded as the most serious of the psychotic disorders. It has a lifetime 
prevalence of about 1 % of the population (Mueser and McGurk, 2004). The onset of 
illness is usually in late adolescence or early adulthood (Jablensky, 1992), and it is more 
common in men than women (Abel et al., 2010).
The Diagnostic Statistical Manual of Mental Disorders’ (DSM-IV) criteria for 
schizophrenia require two of the following characteristic symptoms: 1) delusions, 2) 
hallucinations, 3) disorganized speech, 4) grossly disorganized or catatonic behaviour,
and/or 5) negative symptoms, like apathy or FA. These need to be present for a period of 
one month or longer, as a part of a total illness duration of a minimum of six months, 
which may include a prodromal and a residual phase of illness. Furthermore, disrupted 
occupational or social functioning and/or poor self-care are required to fulfil the 
diagnostic criteria.
The precise aetiology and pathophysiological mechanisms of schizophrenia remains 
uncertain despite more than a century of scientific investigation (Tandon et al., 2008).
Both environmental and genetic factors have been found to contribute to the development 
of the disorder. Studies comparing monozygotic to dizygotic twins estimate the 
heritability of the disorder to be about 80% (Cardno et al., 1999, Sullivan et al., 2003), 
and a number of susceptibility genes have been linked to the disorder (Craddock et al., 
2009, Williams et al., 2011, Ripke et al., 2011, Shayevitz et al., 2012). Environmental 
factors like high paternal age, obstetric complications, cannabis use (Matheson et al., 
2011), urbanicity (Kelly et al., 2010), and migration (Veling and Susser, 2011) also 
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increase susceptibility. However, none of these genetic or environmental factors alone 
have more than a modest contribution to the risk of developing schizophrenia.
1.1.2 Other psychotic disorders
The DSM-IV diagnostic criteria for other non-affective psychotic illnesses are 
similar to that of schizophrenia. The most common psychotic disorders are 
described below.
Schizophreniform disorder includes the same symptom clusters that are required 
for schizophrenia, but the total illness duration is shorter, between 1 and 6 months.
Schizoaffective disorder includes fulfilling the symptom criteria for schizophrenia,
and the presence of affective symptoms for a significant period of the total illness 
duration, but with a minimum two weeks period of having psychotic symptoms in 
the absence of prominent mood symptoms.
In the current study Schizophrenia, schizophreniform disorder and schizoaffective 
disorder are described together as schizophrenia spectrum disorder.
Brief psychotic disorder includes the symptom cluster described in schizophrenia, 
with the total illness duration of more than one day and less than one month.
Delusional disorder is described as non-bizarre delusions of a minimum one
month duration. Other active phase symptoms, like hallucinations or pronounced 
negative symptoms, are not permitted.
Psychosis NOS includes non-organic psychotic syndromes and states that do not 
meet the diagnostic criteria for any specific psychotic disorder, or where 
inadequate or contradictory information makes it impossible to reach a conclusive
diagnosis.
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Affective psychosis is similar in symptomatology to non-affective psychosis, 
however the clinical symptom picture is weighted towards the affective 
component of the illness and therefore is described in the affective/mood section 
in the DSM-IV. Included in this thesis are affective psychoses with mood 
incongruent psychotic symptoms only.
Major depressive disorder and bipolar disorder with mood incongruent psychotic 
symptoms (MDE) are characterized by primary depressive or manic and 
depressive episodes, with co-occurring hallucinations or delusions whose content 
have no apparent relationship to the affective symptoms.
Major depressive disorder and bipolar disorder with mood congruent psychotic 
symptoms are characterized by primary depressive or manic and depressive 
episodes, with co-occurring hallucinations or delusions whose content is related to 
the affective symptoms.
1.1.3  Symptom components of psychotic disorders
The various symptoms seen in psychotic disorders are commonly grouped together and
described as symptom components of the disorders. Most factor analyses of the main 
symptom rating scales, the Positive and Negative Symptom Scale (PANSS) and Scale for 
the Assessment of negative/positive Symptoms (SANS) / (SAPS), have identified three 
to five separate factors (Kay et al., 1987, Kay and Sevy, 1990, Blanchard and Cohen 
2006, Lehoux et al., 2009). The most consistently reported components are listed below:
Positive symptoms include hallucinations and delusions, and represent the reality 
distortion component of psychotic illness. These symptoms are often the most noticeable 
aspects of the illness. Patients may talk to themselves and express beliefs and ideas that 
are implausible or even incomprehensible.
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Negative symptoms include apathy/amotivation, asociality, anhedonia, alogia and flat 
affect (FA). Patients with these symptoms show decreased initiative, poor self care,
social withdrawal, and/or reduced expressivity.
Symptoms within the positive and negative symptom components are the focus of this 
thesis and are thoroughly described in separate sections (1.2 and 1.3).
Cognitive symptoms include impairment of concentration, attention, memory and 
executive function, as well as social cognition, which is the ability to process and apply 
social information. The cognitive component of rating scales like the PANSS may 
provide a rough clinical estimation of possible cognitive deficits. The component has 
limited psychometric properties, however, and cognitive function is better measured by
neurocognitive test batteries (Nuechterlein and Green, 2006). The decline in cognitive 
function often predates the onset of clinical symptoms (Brewer et al., 2005), and 
generally is found to be stable in the long-term course of illness (Heinrichs et al, 1997,
Hoff et al., 2005, Bonner-Jackson et al., 2010). Attenuated forms of cognitive
impairment are also seen in siblings of patients with schizophrenia (Szoke et al., 2005, 
Snitz et al., 2006). Cognitive impairment may be evident across the range of psychotic 
illnesses (Zanelli et al., 2010), with the highest rate occurring in schizophrenia, where 
pervasive cognitive dysfunction has been reported in more than 50% of patients
(Heinrichs et al, 1997). Impairment in social cognition is well documented in 
schizophrenia spectrum disorders (Kohler et al., 2010), and is also seen in bipolar 
disorder and major depressive disorder (Kohler et al., 2011). 
Affective symptoms range from mania to major depression. Depression is common in 
FEP, affecting approximately 50 % of patients during the first year of illness (Romm et 
al., 2010). Depression in FEP patients are associated with female gender, poorer 
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premorbid function, poorer self-esteem, higher levels of insight into own condition and 
an elevated risk of suicide (Romm et al., 2010, 2011, Melle and Barrett, 2012), as well as
reduced level of social functioning and quality of life (Sim et al., 2004).
Excitative symptoms include agitation, hostility and impulsivity. Baseline excitative
symptoms have been found to predict non-remission at three month follow-up (Simonsen 
et al., 2010), and to contribute significantly in explaining service engagement in patients 
with early phase schizophrenia spectrum diagnosis (Johansen et al., 2011).
None of the symptom components or the symptoms within the components are
pathognomonic for any of the psychotic disorders. Patients with the diagnoses described 
above may experience symptoms from all five symptom groups, though negative and 
cognitive symptoms are more pronounced and/or longer lasting in schizophrenia and 
schizoaffective disorder (Gerebaldo et al., 1995a,b, Hebener and Harrow, 2001, Malla et 
al., 2004, Simonsen et al., 2011).
1.1.4 Why study first episode psychosis patients?
Psychotic disorders develop through phases. The period before the onset of symptoms is 
called the premorbid phase. It is followed by the prodromal phase, when symptoms start 
to develop. When the symptoms have developed over a given threshold, and are 
sustained, it is termed the first psychotic episode. Studies of patients with psychotic 
disorders conducted over the last two decades have focused on patients in the early stage 
of illness. A seminal study by Johnstone and colleagues was the first prospective study to 
report Duration of Untreated Psychosis (DUP) as an important predictor of outcome 
(Johnstone et al., 1986). This finding inspired further research and shifted the focused 
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towards early intervention and detection of psychosis (Falloon, 1992). A main focus of 
the ensuing research has been to examine to what extent identification and treatment can 
modify and improve course and outcome, as well as relieve suffering. A benefit of 
studying First Episode Psychosis (FEP) samples is that by following the course of illness 
from as early as possible the effects of recall bias, chronicity, medication and 
institutionalisation are minimized. Also, by comparing patients at a similar stage of 
illness the heterogeneity in the sample is reduced.  
FEP studies often include a broad spectrum of diagnoses within the psychosis spectrum 
both because of initial diagnostic instability (Baldwin et al., 2005, Haahr et al., 2008), 
and because affective and non-affective psychosis share many characteristics including 
symptomatology. Studying symptoms and symptom components in a broad spectrum of 
psychotic disorders allows for larger samples and may illuminate how core symptoms in 
psychotic disorders are related to each other and how they affect functioning and 
outcome.
1.1.5 Longitudinal studies of psychotic disorders 
Longitudinal studies provide us with important data on illness course and outcome. 
Results from the earliest longitudinal studies of patients with psychotic disorders were 
reviewed in a seminal study by Shepherd and colleagues. These studies reported a 
deteriorating course in 62 % of patients with schizophrenia assessed between1900-1929
(Shepherd et al., 1989). This almost uniformly pessimistic view was nuanced by a later 
study that described schizophrenia as a heterogeneous disorder with eight different 
courses of illness and end states ranging from recovery to severe illness (Bleuler, 1978). 
The clinical data in this study was reassessed using today’s diagnostic criteria (DSM-IV), 
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and it was found that 61 of the original 189 schizophrenia patients were better described 
as having a psychotic disorder other than schizophrenia (Modestin et al., 2003). In a 
study published in 1980, Ciompi and colleagues retrospectively assessed 289 patients 
with schizophrenia for an average of 37 years after their first admission. They reported 
that about three fifths of the patients had a favourable outcome. The results further
challenged the earlier view of schizophrenia as an illness with globally poor prognosis. 
The study had several limitations, however. The median age at onset of illness was high, 
all participants were inpatients at the time of inclusion, and diagnosis was made without 
reference to any international diagnostic classification system. Later studies have 
improved methodology by having a prospective design, using standardized diagnostic 
criteria and using epidemiological and more representative patient samples that are 
followed from earlier in the course of illness. To better compare the results in different 
studies, criteria for remission have been standardized (Andreassen et al., 2005), and now 
include not only the absence of positive symptoms but also a low score, or the absence, 
of significant negative symptoms. Using these criteria the Australian FEP study, EPPIC,
found that 36.8 % of patients were in remission at seven year follow-up. This rate is 
similar to results from shorter duration studies, also applying the Andreassen’s remission 
criteria that were reviewed in the same paper (Henry et al., 2010).
Even if the earlier studies report a better outcome, with a significant proportion of the 
patients reaching recovery, many patients with psychotic disorders still experience a 
chronic course of illness. Poor outcome has been found to be predicted by male gender, 
early onset, insidious onset, long DUP and the severity of negative and cognitive 
symptoms (Ho et al., 1998, Perkins et al., 2005, Milev et al., 2007, White et al., 2009, 
Bertelsen et al., 2009). The Danish FEP study, OPUS, reported that 13 % of their 265 
patient were institutionalised at five year follow-up. They further reported that 18 % of 
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the patients were in recovery. A large proportion of the sample thus experiences a 
relapsing remitting course of illness.
Longitudinal studies from the early eighties onwards widened their scope to focus more 
closely on symptom development. The Chestnut Lodge follow-up study described 
symptom development retrospectively in an inpatient population followed over five years 
after the first admission using the SAPS/SANS (McGlashan, 1984). The natural history 
of schizophrenia was summarized as follows: “In first or early episodes positive 
symptoms are frequent, negative symptoms are infrequent, and both types are unstable 
fluctuating, and usually treatment responsive. In sub-acute/chronic stages of the illness 
negative symptoms increase in prevalence, are at least as common as positive symptoms, 
and fluctuate less. In the latter stages of the illness, negative symptoms are quite stable 
and usually dominate the clinical picture” (McGlashan and Fenton, 1992). Later studies 
of symptom development have strengthened methodology by being prospective and 
following epidemiologic samples from the first psychotic episode. These studies have 
also often included a wider diagnostic group of psychotic disorders. However, the studies 
that focus on symptom development have two main limitations. Firstly, most studies 
focus on symptom components rather than specific symptoms (Eaton et al., 1995, Breier 
et al., 1991, Milev et al., 2005, Siegel et al., 2006, Bertelsen et al., 2009, White et al., 
2009). With regard to positive symptoms this implies that patients with hallucinations 
and delusions are not looked at separately. With regard to negative symptoms this 
method makes data especially difficult to interpret as the negative symptom construct
consists of several symptoms, and different negative symptom assessment scales include 
and emphasize different symptoms. The second main limitation is that most studies that 
do follow individual symptoms (McGlashan et al., 1992, Arnt et al., 1996) report mean 
prevalence of a given symptom at each point of follow-up rather than following 
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individual patients and looking for clusters of patients with similar symptom 
development. A reason why earlier studies have reported on mean values could be a
lingering notion that symptoms in psychotic disorders are stable, especially with regard 
to negative symptoms. As described, the above studies show that schizophrenia and other 
psychotic disorders are mostly relapsing remitting disorders, and that only a minority of 
patients follow a chronic course. Studies that have reported stable mean values for 
symptoms over time in psychotic disorders appear to have overlooked the relapsing and 
remitting nature of the disorders, as patients with fluctuating symptoms may have 
equalled each-other out, giving the appearance of higher symptom stability in the total 
sample. Longitudinal studies of specific positive and negative symptoms where different 
symptom trajectories and profiles are documented may thus further inform this field of 
research.
1.2 Positive symptoms of psychotic disorders
The term positive symptoms describe the reality distortion component of psychotic 
illnesses including hallucinations and delusions. Since the advent of neuroleptic 
treatment this symptom group has been the most extensively studied component of 
psychotic disorders. Positive symptoms are thought to result in part from prefrontal-
limbic dopamine imbalance (Howes and Kapur, 2009, Heinz and Schalgenhauf, 2010),
and dopaminergic models are supported by the effect of antipsychotic medication 
through the blockade of dopamine receptors. These models only partly explain the 
symptoms, and an ongoing work is progressing to map out the role of other 
neurotransmitter systems as well as structural changes to the pathogenesis of positive 
symptoms.
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Hallucinations and delusions are commonly described together. However, it is 
recognized that these symptoms often occur separately, and possibly give a separate 
contribution to outcome measures. A number of studies have recorded the presence of 
both hallucinations and delusions in patient samples over time and related individual 
symptoms to associated symptoms and outcome factors (Fenton and McGlashan, 1991,
1992, Addington et al., 1993, Harrow et al., 2004). A 20 year follow-up study found that 
hallucinations and delusions correlated strongly at two year follow-up (r=.85), but that 
the correlation weakened during the follow-up period (r=.53 at 20 years). Continuous 
delusional activity was present in both patients with schizophrenia and other psychotic 
disorders, including affective psychosis), and persistent delusional activity strongly 
predicted work disability (Harrow and Jobe, 2010). 
1.2.1 Delusions
Delusions are erroneous beliefs that usually involve a misinterpretation of perceptions or 
experiences, and are described in the DSM-IV as “A false belief based on incorrect 
inference about external reality that is firmly sustained despite what almost everyone else 
believes and despite what constitutes the convertible and obvious proof or evidence to the 
contrary. The belief is not ordinarily accepted by the members of the persons culture and 
subculture (e.g. is not an article of the persons faith)” (APA, 2000). The delusionary 
content may include a variety of themes (persecutory, referential, somatic, religious or 
grandiose), and persecutory delusions are the most common. Delusions are suggested to 
arise from anomalies in reasoning processes, and studies have shown that patients with 
delusions show: 1) jumping to conclusion bias, 2) attributional bias, and 3) difficulties 
appreciating other peoples’ perspectives on theory of mind tasks (Langdon et al., 2010).
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1.2.2 Delusions without hallucinations
Clinical studies that recognize a group of patients who experience delusional ideation 
without also suffering from hallucinations, usually focus on delusional disorder (Munro, 
1995, Opjordsmoen, 1988, 1989a). This diagnosis is associated with later onset of illness
and better outcome (Opjordsmoen, 1989b), including less hospitalizations and higher rate 
of employment, compared to a schizophrenia sample (Marneros et al., 2012). Patients 
from other diagnostic categories who experience delusions only have received little 
specific attention.
1.2.3 Hallucinations
A hallucination is a percept-like experience occurring in the absence of an external 
stimulus. The percept-like experience has the full force and impact of a real perception, 
and is unwilled and cannot be readily controlled (Slade, 1976). Unlike illusions, 
hallucinations arise de novo and occur alongside normal perceptions (Jaspers, 1969). 
Hallucinations may arise from a variety of sensory systems, giving rise to auditory, 
visual, somatosensory and olfactory hallucinations. Auditory hallucinations are the 
commonest form, and these may range from elementary noises to fully formed voices. It 
has been suggested that auditory hallucinations arise from a deficit in source monitoring,
whereby inner speech is misidentified as external voices (Firth et al., 1987, Bentall et al., 
1990). Studies using manipulated auditory feedback of patients’ own voices have 
reported that patients with schizophrenia tended to misidentify their own distorted voice
as someone else’s (Cahill, 1996, Johns et al., 2001). Johns and colleagues furthermore 
reported similar, but less marked, misattribution deficits in patients with schizophrenia 
without a history of hallucinations, and that patients with affective psychosis tended to 
report that they were “unsure” about the origin of the voice rather than to misattribute 
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(Johns et al., 2006). Deficit in source monitoring thus seem to be a mechanism shared 
between diagnoses and also in patients with delusions both with and without 
hallucinations.
1.2.4 Hallucinations without delusions
Like delusions, hallucinations can occur mono-symptomatically, without coexisting 
delusions. The number of studies describing patients who experience hallucinations, but 
not delusions is limited, but the symptom-profile has been described in non-clinical 
samples. A study comparing a group of voice-hearers without additional 
psychopathology to a normal (non-voice-hearing) control group, found that the voice-
hearing group had poorer global functioning (Sommer et al., 2010). Another study,
comparing a similar group of voice-hearers to a schizophrenia patient group, found that 
while the form of hallucinations was similar between patient and non-patient groups, 
other differences existed between the groups in terms of hallucinatory content, emotional 
quality and locus of control of the voices, with the non-clinical group experiencing the 
voices as less threatening and more controllable than the patient group (Honig et al., 
1998). Mauri and colleagues have described a patient group where hallucinations, rather 
than delusions, were the dominating symptom (Mauri et al., 2006, 2008). The group was 
labeled “Hallucinatory Disorder” and the patients were found to be older, have higher 
academic achievement, score better on insight measures, and to have higher suicidality 
compared to a schizophrenia patient group.
1.2.5 Positive symptoms and suicidality
Suicide is one of the major contributors to the excess mortality reported in psychotic 
disorders (Pompili et al., 2011). Approximately 2-5% of deaths in FEP patients, as 
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reported in long-term follow-up studies, are a result of suicide (Palmer et al., 2005, Dutta 
et al., 2011). Suicidal acts and suicide are most common in the early stage of illness 
(Nordentoft et al., 2002, Dutta et al., 2010, Bertelsen et al., 2007, Barrett et al., 2010),
and most completed suicides occur in the first decade of illness, and 50 % of these occur 
in the first two years after illness onset (Montross et al., 2005). Several studies have 
related delusions and hallucinations to suicidality. A study investigating the relationship 
between delusions and suicidality found no evidence of a significant correlation between 
delusions at admission, and a history of suicidal ideation or suicide attempts. The study 
reviewed the existing literature, and concluded against delusions as a separate predictor 
of suicidality (Grunebaum et al., 2001). A small number of studies have showed that 
hallucinations is a risk factor for suicidality (Fialko et al., 2006, Kaplan and Harrow,
1996), but a clear association between hallucination and suicidality is not established
(Harkavy –Friedman et al., 2003). The OPUS study found that hallucinations at two year 
follow-up predicted suicidality (plans and attempts) in FEP (Bertlesen et al., 2007). The 
above studies, however, looked at data cross-sectionally and recorded the number of 
patients suffering from any one symptom at a particular time rather than showing 
longitudinal symptom profiles and their separate correlates. Prior to our study patients 
with hallucinations only and delusions only had not been compared on measures of 
suicidality.
1.3 Negative symptoms of psychotic disorders
The negative symptoms construct include apathy/avolition, asociality, anhedonia, 
inattention, alogia and flat affect (FA). The etiology of these symptoms is still poorly 
understood, with findings implying multiple and complex neurophysiological 
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mechanisms underlying symptom expression (Linscott and van Os, 2011, Howes and 
Kapur, 2009). The negative symptom group has been found to be cross-sectionally and 
longitudinally independent from the positive symptom group (Kirkpatrick et al., 2001,
Drake et al., 2003), and factor analytic studies confirm the negative symptom component 
as being separate from the cognitive, affective as well as excitative symptom components
(Kay and Sevy, 1990, Emsley et al., 2003, Blanchard and Cohen, 2006, Foussias and 
Remington, 2010). Negative symptoms are often the first symptoms to develop in 
patients with psychotic illness (Hafner et al., 1999). These symptoms adversely influence
functioning and outcome (Ho et al., 1998, Bowie et al., 2006, White et al., 2009, Ventura 
et al., 2009, Bottlender et al., 2010), and are associated with slower recovery and longer 
periods of hospitalization (Hwu et al., 2002). The symptoms are treatment resistant 
(Kirkpatrick et al., 2006, Makinen et al., 2008), and often persist after positive psychotic 
symptoms have been successfully treated. 
Most long-term follow-up studies of negative symptoms report mean levels cross-
sectionally rather than investigating longitudinal symptom trajectories. Harrow and 
colleagues, however, followed 42 young patients with schizophrenia and schizoaffective 
disorder and found that 19 % had enduring, 41 % episodic, and 40 % no negative 
symptoms over a ten year follow-up period. Enduring symptoms were defined as being 
above threshold level (score of >1 on at least one item of the Pogue-Geile and Harrow’s 
Negative Symptom Scale) at three follow-up assessments (Herbener and Harrow, 2001).
These patients were also compared to a group with affective psychosis and a group with 
non-psychotic depression. Enduring negative symptoms had lower prevalence in non-
schizophrenic illness, but similar level of severity, persistence and relation to symptom 
correlates (medication, positive symptoms and depression) was observed (Herbener and 
Harrow, 2001, 2004). A recent study of FE schizophrenia patients found that 24% of 
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patients had persistent negative symptoms at ten year follow up. This study also reported 
that 41% of their participants had negative symptoms at baseline (Makinen et al., 2010). 
The study did not have more than one point of follow up, however, and neither this nor 
Herbener and Harrow’s study examined individual negative symptoms.
Most studies that report symptom stability over time emphasize the stability of negative 
symptoms over positive symptoms (Pougue-Geile and Harrow, 1985, Fenton and
McGlashan, 1992, Drake et al., 2003, Makinen, 2008). However, some studies indicate a 
more fluid symptom picture also for negative symptoms. Edwards and colleagues 
examined negative symptoms in a FEP sample followed three times over a one year 
period. Persistent negative symptoms was found in 4- 41 % of the sample, depending on 
the criteria used to define enduring symptoms (Edwards et al., 1999).
Negative symptoms are often studied together, with studies reporting negative 
component sum scores rather than scores on individual symptoms (Edwards et al., 1999, 
Hebener and Harrow, 2001, Makinenen al., 2010, Chang et al., 2011). However, the
negative symptom construct represents a heterogeneous symptom group. Different 
symptom scales, like the PANSS, SANS and the Schedule for the Deficit Syndrome 
(SDS) differ on how they define the individual negative symptoms and what negative 
symptoms that are focused on and measured, and no clear consensus exists on how to 
best measure this group of symptoms. Factor analyses of the negative symptom 
component of assessment batteries like the PANSS and the SANS have indicated that 
alogia is better explained as part of the cognitive component, and that the remaining 
negative symptoms should be seen as two separate factors: an experiential factor where 
apathy/amotivation is the main feature, and an expressive factor where FA is the main 
feature (Blanchard and Cohen, 2006, Messinger et al., 2011). The finding has been 
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replicated in factor analyses of two new negative symptom measures, the Clinical 
Assessment Interview for Negative Symptoms (CAINS) and the Brief Negative 
Symptom Scale (BNSS) (Horan et al., 2011, Kirkpatrick et al., 2011).
In 2005 the National Institute for Mental Health (NIMH) organized the Consensus 
Development Conference on Negative Symptoms to further the study of negative 
symptoms. An expert group was assembled with the aim of improving our understanding 
of negative symptoms so as to facilitate treatment development. The group defined the 
key negative symptoms described above and released a consensus statement that 
encouraged the longitudinal study of individual negative symptoms (Kirkpatrick et al., 
2006). Previous literature is lacking in prospective long-tem studies of well described 
epidemiological FEP samples that follow the symptom development of individual 
negative symptoms. Following the incentive from the NIMH consensus statement on
negative symptoms, and the conclusion from factor analytic studies of negative 
symptoms, we chose to focus on the longitudinal symptom development of apathy and 
FA in our patient sample.
1.3.1 Apathy
Apathy is described as a neuropsychiatric symptom associated with dysfunction of the 
prefrontal cortex and its subcortical connections (Marin et al., 1991b, Stuss et al., 2002, 
Tekin et al., 2002).  It is highly prevalent in neuropsychiatric conditions such as 
Alzheimer’s Disease and Parkinson’s Disease, in which it has been associated with 
functional decline (Starkstein et al., 2006), worse course and outcome (Starkstein et al., 
2006, 2009), and poor executive function (McPherson et al. 2002, Pluck et al., 2002, Tsoi 
et al. 2008). 
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Apathy is also well documented in psychotic disorders (Barch, 2008, Foussias and 
Remington, 2010, Messinger et al., 2011), and the terms apathy, avolition and 
amotivation are used interchangeably in the literature (Foussias and Remington, 2010). 
Apathy in psychotic disorders was first described by Kraepelin in 1919. It was later
defined by Marin as “the lack of motivation not attributed to diminished levels of 
consciousness, cognitive impairment or emotional distress” (Marin, 1991a). This 
definition forms the basis for the commonly used assessment tool Apathy Evaluation 
Scale (AES) (Marin et al., 1991b). Studies of apathy in both neuropsychiatric and 
psychotic disorders have found apathy to be a primary symptom, with only a small 
percent of the variance in the apathy score being explained by depression, side-effects of 
medication or psychotic withdrawal (Faerden et al., 2009a, Kiang et al., 2003).
Studies of apathy in psychotic disorders have found an association between apathy and 
longer DUP (Malla et al., 2002), poorer general functioning (Kiang et al., 2003, Foussias 
et al., 2009, 2011), aberrant executive function (Roth et al., 2004), and reduced prefrontal 
cortical volume (Roth et al., 2004). The generalizability of these findings is limited by 
cross-sectional designs, small sample sizes, and inclusion of patients with long illness 
durations. 
Faerden and colleagues used the clinician version of the AES (AES-C) to examine apathy 
in FEP. They investigated 103 patients at baseline and 84 patients at one year follow-up,
and found that 51 % of patients at baseline, and 40 % at one year follow-up, were 
clinically apathetic (AES-C score > 27). They also found that apathy at one year follow-
up was predicted by male gender, long DUP, a diagnosis within the schizophrenia 
spectrum, and baseline apathy. They further provided evidence for the association 
between apathy and poorer functioning, as apathy was found to be significantly and 
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independently related to functioning at both baseline and follow-up (Faerden et al., 
2009b, 2010).
1.3.2 Apathy and subjective quality of life
Quality of life (QoL) is an important outcome variable in psychotic disorders. Studies 
often differentiate objective from subjective QoL. Objective QoL refers to role 
fulfillment, financial situation, social functioning and daily activities, whereas subjective 
QoL focuses on patients’ self-reported satisfaction with life and over-all sense of 
wellbeing. Subjective QoL has been reported to be lower in patients with psychotic 
disorders (Malla and Payne, 2005), and also lower in patients with first episode 
schizophrenia and schizoaffective disorder compared to a chronic patient sample (Priebe 
et al., 2000). Studies of FEP patients have found that lower subjective QoL is associated 
with depression (Malla and Payne, 2005, Renwick et al., 2011), longer DUP, and
younger age at onset (Malla and Payne, 2004). While Gorna and colleagues reported a 
significant association between subjective QoL and both positive and negative symptoms 
in first episode schizophrenia (Gorna et al., 2008), Melle and colleagues failed to find 
such relationships in the two year follow-up study of the TIPS sample using the three
factor model of PANSS to measure symptom components (Melle et al., 2010).
The association between apathy and patient rated, subjective QoL is contested. In 
Alzheimer’s disease patient’s careers, but not patients themselves, rated quality of life as 
poorer in those with high apathy levels (Karttunen et al., 2010). In Parkinson’ disease 
patient’s own rating of QoL has been associated with higher apathy scores (Barone et al., 
2009; Benito-León et al., 2011). In psychotic disorders apathy has been viewed as an 
ego-syntonic symptom in patients indifferent to their own state and surroundings 
(Bleuler, 1950). A further study found apathy to be the negative symptom causing the 
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most distress (Selten et al., 2000). In our study we sought to further explore the 
relationship between apathy and subjective quality of life.
1.3.3 Flat affect
Flat affect is described as unchanging facial expression, paucity of gestures, and affective 
non-responsiveness (Kay et al., 1987). A study comparing patients with schizophrenia 
and with depression to healthy controls found that the patient groups had similar deficits 
in spontaneous and posed emotional expressiveness, smiling and co-verbal gestures
(Tremeau et al., 2005). FA is also documented in neuropsychiatric disorders like 
Parkinson’s Disease and right hemisphere brain damage (Borod et al., 1989). In patients 
with schizophrenia FA has been reported to be present at the onset of illness (Shtasel et 
al., 1992), and associated with earlier onset, poorer premorbid adjustment and poorer
verbal memory (Gur et al., 2006). Malla and colleagues found that FA was predicted by
male gender, younger age of onset, a diagnosis of schizophrenia and length of prodromal 
period in an FEP population. The same mean level of FA was reported for patients with 
schizophrenia compared to a broad spectrum of other psychotic disorders (Malla et al.,
2002). At one year follow-up Malla and colleagues found that FA was an indicator of 
poor response to treatment, and a predictor of the development of persistent negative 
symptoms (Malla et al., 2004). These findings have been replicated in a recent one year 
follow-up study (Gladerisi et al., 2012) that additionally found FA to be the most 
persistant negative symptom. Kelley and colleagues investigated FA, avolition, alogia 
and anhedonia separately using the SANS at baseline and four points of follow-up over 
one year in both a chronic and a first episode schizophrenia sample (Kelley et al., 2008). 
The study concluded that levels of FA were largely stable over one year, in contrast with 
the other negative symptoms that followed a more fluctuating course. 
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Laboratory studies of patients with schizophrenia have reported reduced facial 
expressions during social interaction (Krause et al., 1989), and watching emotional films 
(Berenbaum and Oltmanns, 1992) and cartoons (Dworkin, 1992). FA, the deficit in 
expression of emotion, has been shown to be a separate factor to anhedonia, the deficit in 
experiencing pleasure (Foussias and Remington, 2010). Kring and colleagues found that 
when watching both positive and negative emotional films, patients with schizophrenia
were less facially expressive than normal subjects, yet they reported experiencing as 
much, or more, emotion than did the normal controls (Kring et al., 1993). FA may thus 
be a failure to express emotional states rather than a genuine lack of emotionality. Other 
studies contest these findings and describe FA as incorporating both an affective and a 
neuromotor deficit (Dworkin et al., 1996).
1.3.4 Flat affect and social functioning
Deficits in social functioning are common in psychotic disorders and have been found to 
precede the first psychotic episode (Hafner et al., 1995, Woods et al., 2009). In the Israeli 
draft board study of patients who later developed schizophrenia, asymptomatic future 
patients were found to have poorer social functioning at the age of 16 (Reichenberg et al., 
2002). 
Studies of negative symptoms have found a significant association between this symptom 
group and reduced social functioning over time (Ho et al., 1998, Shatsel et al., 1992, 
Lysaker and Davis 2004). The lack of observable expressive behavior seen in patients 
with FA is likely to have detrimental interpersonal consequences. A study found that 
healthy individuals were less expressive when they interacted with a patient with 
schizophrenia than with healthy subjects (Krause et al., 1992). A one year follow-up
study of patients with schizophrenia found that patients with FA had poorer social 
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outcome compared to patients without FA (Gur et al., 2006).  The relationship between 
FA and social functioning beyond one year had not been described prior to our study. 
1.4 Diagnostic categories versus dimensions
How to best describe psychiatric illness has been an ongoing debate since the first 
diagnostic systems were constructed. The two main classification systems, the 
International Classification of Diseases (ICD) and the DSM divide non organic psychosis 
into affective/mood disorders and non-affective/schizophrenia disorders. Schizoaffective 
disorder, where both schizophrenia- type symptoms and affective symptoms are equally 
pronounced, is categorized under the schizophrenia spectrum disorders. The division into 
affective and non-affective psychosis may not, however, reflect the difference in 
aetiology, disease processes and prognosis that we assume when we describe two 
conditions as separate entities. Non-affective psychotic disorders, affective psychotic 
disorders and purely affective disorders share many of the same risk factors and 
symptomatology. Studies show that schizophrenia and bipolar illness have similar 
heritability rates (Chicon et al., 2009), and share affected neurotransmitter systems 
(dopamine, serotonin, Gamma-aminobutyric acid, and glutamate) (Freedman et al., 2003, 
Ackenheil et al., 2001, Cherlyn et al., 2010), as well as symptom response to the same 
psychoactive medication (Citrome et al., 2005). In the last two decades new tools have 
been developed to study neurobiological vulnerability markers, or endophenotypes, that 
bridge genotype and clinical phenotype. These tools have revealed that affective and non 
affective psychotic disorders share many of the same biological correlates. Studies using 
MRI imaging have found similar type, but quantitatively different, structural brain 
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changes in schizophrenia and bipolar disorder (Strakowski et al., 2005, Strasser et al., 
2005, Morgan et al., 2007). Similarly, recent cross diagnostic studies have found little or 
no difference between psychotic disorders on neurocognitive functioning (Simonsen et 
al. 2011, Lewandowski, 2011). The conditions furthermore share several susceptibility 
genes (Craddock et al., 2009, Williams et al., 2011, Skal et al., 2011).
Studies of symptomatology in healthy populations have shown attenuated positive and 
negative symptoms in non-clinical populations (Van Os et al., 2009). The same 
symptoms have also been found in neuropsychiatric conditions like Parkinson’s disease 
and Alzheimer’s disease (Barone et al, 2009, Kartuunen et al., 2010). These findings, 
together with the data that describes the similarities between affective and non affective 
psychosis, suggest that psychotic symptoms are experienced on a continuum, stretching 
from the well, non clinical population to the severely ill, and over several diagnostic 
categories. The “psychosis-proneness-persistence-impairment model” of psychotic 
disorder details this psychosis continuum (Van Os et al., 2009), and describes how the 
usually transitory psychotic experiences can become more persistent psychotic 
experiences with a need for clinical care due to environmental and psychological risk 
factors such as psychological trauma, cannabis and urbanicity.
These findings seems to imply that the disease processes we describe as schizophrenia,
schizoaffective disorder and bipolar disorder could be better described dimensionally, as 
syndromes with shared symptom components, and that the disorders differ from each
other quantitatively rather than qualitatively. Longitudinal studies of patients from 
different diagnostic categories, but with overlapping phenotype and genotype, may 
further illuminate the pathogenesis of symptoms and syndromes in psychotic illness, and 
help us learn more about these symptoms and how they are related to each other. 
Following patients with similar symptoms profiles over time give us the possibility of 
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uncovering relationships between these symptom profiles and functional and outcome 
variables.
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2. Aims
This thesis aims to explore individual positive and negative symptoms in a large, 
epidemiologic sample of FEP patients. By studying single symptoms longitudinally and 
identifying distinct longitudinal symptom profiles, we aimed to increase our 
understanding of how these symptoms develop over time, their relation to other 
symptoms, and to outcome variables known to be affected in psychotic disorders. The
thesis focuses on a broad group of FEP patients with shared symptomatology, followed
for ten years from the onset of illness, with up to six assessments.
In paper I the main aim was to examine if it was possible to identify subgroups of 
patients who, during a five year follow-up period, had suffered either from hallucinations
only or delusions only, and to examine if these groups differed on baseline variables 
(demographic characteristics, DUP, premorbid functioning) and clinical measures,
including insight. Furthermore, we wanted to explore if hallucinations, to a greater extent
than delusions, were related to suicidality and completed suicides.
In paper II the main aim was to assess the prevalence of self-reported apathy at ten years 
follow-up, and to explore symptom development through a longitudinal clinician rated 
proxy-measures of apathy (PANSS N2+N4). Furthermore, we wanted to investigate if
apathy had a significant independent contribution to global functioning and to subjective 
quality of life scores ten years after the first psychotic episode.
In paper III the main aim was to identify groups of patients with different flat affect (FA) 
trajectories and to examine the prevalence and stability of FA over a ten year period. We 
also wanted to examine if the FA trajectory groups differed in outcome measure at ten
years follow-up, and in social functioning over the ten year follow-up period.
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3. Method
3.1 Design
The TIPS (Early Treatment and Intervention in Psychosis) project is a large, longitudinal 
study of an epidemiologic sample of FEP patients. The study protocol was planned and 
initiated from 1995 by the study research committee; Thomas McGlashan (Chair), Ulrik 
Haahr, Jan Olav Johannessen, T.K. Larsen, Ingrid Melle, Stein Opjordsmoen, Bjørn R.
Rund, Erik Simonsen, Per Vaglum, and Svein Friis. The study was designed to identify 
and follow consecutively admitted FEP patients from four Scandinavian health care 
sectors (North and South sector, Rogaland County, Norway, Ullevaal Sector, Oslo, 
Norway, and Fjorden mid-sector, Roskilde, Denmark). Patients received publicly funded, 
catchment based, specialist psychiatric care. Patients were included between 1997-2000,
after equivalent treatment programs for FEP patients had been established in the health 
care sectors involved. The TIPS project is an early intervention in psychosis study. The 
primary aim of the original study was to answer the following research questions: 
x Is it possible to reduce the duration of untreated psychosis (DUP) through an 
early detection program?
x Would a reduction in DUP be followed by a difference in the course of illness, 
and can this difference be explained by the reduction of DUP?
In order to answer these questions patients from the two healthcare sectors in Rogaland 
County (ED group) were exposed to an early detection and compared to patients from the 
Oslo and Roskilde healthcare sector (no-ED group) who engaged with the services as 
previously done. The early detection program consisted of public information campaigns, 
education of teachers, social workers and GPs, a telephone “hotline” and an offer of 
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assessment within 24 hours of service contact. The early detection campaign successfully 
reduced DUP (Melle et al., 2004), answering the first main research question of the 
study. Patients in the ED and the no-ED regions were compared with regard to clinical 
severity, function, suicidality and other outcome measures. At baseline, ED patients were 
found to have lower symptom load (positive, negative and general symptoms), better 
social functioning, and lower suicidality (Melle et al., 2004, 2005, 2006), answering the 
second main research question. For the ED / no-ED comparison part of the study the 
design was quasi-experimental parallel control.
The study described in this thesis did not distinguish between the ED and no-ED patients, 
but followed the whole patient sample. The design of the described studies is hence 
prospective and longitudinal.
The overall study design, samples, assessment instruments, and results of previous 
assessments are carefully detailed in several reports (Larsen et al., 2001, Melle et al., 
2004). 
3.2 Procedure
3.2.1 Inclusion and treatment                                                                                         
Patients were recruited to the study as they presented to the services. As described above,
this process was different in the ED region compared to the no-ED, however once 
recruited to the study the same inclusion criteria and assessment protocol applied. 
Patients in the four healthcare sectors were offered the same basic treatment after 
inclusion to the project:
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1. Defined treatment algorithms for antipsychotic medication (low dose second-
generation antipsychotic medication). 
2. Individual psychosocial treatment (a trained therapist offering weekly sessions).
3. Psycho-educational family work (multifamily groups).
We chose to define inclusion/start of project as the start of first adequate treatment. 
Adequate treatment was defined as the start of structured treatment with antipsychotic 
medication, or the start of hospitalization in highly staffed psychiatric wards organized to 
manage disturbing psychotic symptoms.
3.2.2 Follow-up assessments 
Following the initial inclusion in the study and baseline assessment, patients were 
reassessed at three months, and one, two, five and ten years. 
3.3 Participants
3.3.1 Participants at baseline
Inclusion and exclusion criteria for the TIPS study are listed below:
1) A first episode psychosis (3$166VFRUHRQRQHRUPRUHRISRVLWLYHVXEVFDOH
items P1, 3, 5 or 6 or on general subscale GIRUGD\V
2) Meeting the DSM-IV criteria for schizophrenia, schizophreniform disorder, 
schizoaffective disorder, brief psychotic episode, delusional disorder, affective 
psychosis with mood-incongruent psychotic features or psychotic disorder not 
otherwise specified.
3) Age 18–65 years (15-65 in Rogaland).
4) IQ >70.
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5) Living in the catchment area of one of the four healthcare sectors.
6) Understanding/speaking a Scandinavian language.
7) Ability to give written, informed consent.
The exclusion criteria were:
1) Having received adequate prior antipsychotic treatment (antipsychotic medication 
> 3.5 haloperidol equivalents for >12 weeks or until psychotic symptoms 
remission) and an organic- or substance-induced psychosis. 
2) Having a neurological or endocrine disorder related to psychosis.
Both inpatients and outpatients were included in the study. Altogether 301 patients were 
included from 1997 through 2000. 
3.3.2 Participants in the papers included in this thesis
The three papers included in this thesis all use patients drawn from the TIPS sample 
described above. The different studies, however, focused on different subgroups of 
patients and followed them for different lengths of time.
The table below describes the number of patients and length of follow-up in the three 
studies.
Paper I Paper II Paper III
Length of follow-up 5 yrs. 10 yrs. 10 yrs.
Number of participants 301 178 184
Use of data All points of measure 
(baseline -5 yrs.)
Baseline + 10 yrs.
(N2 and N4 used at all 
points of measure)
All points of measure 
(baseline -10 yrs)
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3.3.3 Drop out analyses at ten years
Included Not included
Total N, % Total N, %
Gender (males) 186 104 (56) 115 72 (63)
Marital status 186 113
Single 131 (73) 34 (61)
Living together/married 31 (17) 13 (23)
Ethnicity Scandinavian 186 178 (96) 115 102 (89)
Diagnosis Core schizophrenia at baseline 186 116 (62) 115 72 (63)
Abuse Alcohol 186 23 (12) 115 26 (21)
Drugs 186 41 (22) 115 29 (25)
N Median(min-max) N Median (min-max)
Age 186 25 (15-61) 115 24 (15-63)
Years of education 175 12 (7-22) 110 11 (8-20)
Premorbid Adjustment Scale
Social level childhood 183 0.5 (0-5) 110 1 (0-5)
Academic level childhood 183 1.5 (0-6) 110 1.75 (0-5)
Social level last score 183 1.5 (0-6) 110 2.0 (0-6)
Academic level last score 183 2.0 (0-6) 110 2.5 (0-6)
Duration of untreated psychosis in weeks ) 186 6 (0-520) 115 17 (0-1196)
Baseline psychopathology (median, min-max)
PANSS positive component 186 15 (5-28) 114 15 (8-26)
PANSS negative component 186 18 (10-50) 112 19 (10-64)
PANSS cognitive component 186 7 (3-17) 111 7 (3-20)
PANSS depressive component 186 12 (5-23) 112 13 (5-24)
PANSS excitative component 186 8 (5-31) 112 9 (5-27)
GAF-f 186 30 (10-70) 113 30 (14-63)
Level of functioning (Strauss-Carpenter scale)
Working last year 169 2 (0-4) 103 1 (0-4)
Meeting friends last year 180 3 (0-4) 111 3 (0-4)
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The above drop out analyses show few significant differences between the participant at 
baseline and the remaining participants at ten years follow-up. The non-participant group 
had a significantly higher percentage of non-Scandinavian patients (p=0.020), higher rate 
of alcohol abuse (p=0.05), shorter education (p=0.035), a longer DUP (p=0.002) and 
lower rate of employment in the year before inclusion (p=0.006).The analyses were
repeated comparing only the patients included in paper II (N=178) and in paper III 
(N=184) without finding additional differences between participants at ten years and 
baseline participants. These analyses included baseline levels of proxy measures of 
apathy (PANSS N2 and N4) and of FA (PANSS N1).
3.4 Measurements
3.4.1 Main assessment instruments
Measures conducted at baseline only: Duration of untreated psychosis (DUP) was 
measured as the time in weeks from the first positive psychotic symptoms (PANSS score 
of four or more on Positive scale items one, three, five or six or General scale item nine) 
to the start of the first adequate treatment of psychosis (i.e., admission to the study).  
Premorbid functioning was measured by the Premorbid Assessment of Functioning Scale 
(PAS). A previous analysis identified two premorbid dimensions: social consisting of 
PAS items social isolation and peer relationships and academic which comprised school 
performance and school adaptation (Larsen et al., 2004). 
Diagnostic assessment: The structured clinical interview for the DSM-IV (SCID) was 
used for diagnostic purposes (Spitzer et al., 1992).  
Symptoms: Symptom levels were measured by the Positive and Negative Syndrome 
Scale (PANSS) (Kay et al., 1987), and symptom domains were represented by the 
corresponding PANSS components (positive, negative, excitative, cognitive and 
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depressive) (Kay and Sevy, 1990, Bentsen et al., 1996). Individual items were used to 
follow specific symptoms (see table below).
Depression was assessed by the Calgary Depression Scale for Schizophrenia (CDSS) 
(Addington et al., 1992). Apathy was measured with the self report version of the Apathy 
Evaluation Scale (AES-S) (see further details, 3.4.4).
Function and quality of life: Global functioning was measured by the Global
Assessment of Functioning Scale (GAF) (Endicott et al., 1976), and split into symptom
[GAFs] and function scores [GAFf] to improve psychometric properties (Pedersen et al., 
2007).
Employment and ability to live independently was measured with the Strauss Carpenter 
Level of Functioning Scale (SCLFS) (Strauss and Carpenter, 1974).
Objective social functioning was measured using Lehman’s Quality of Life Interview (L-
QoLI) items, brief version (Lehman et al., 1988). It consists of three items: 1. How often 
do you visit friends? 2. How often do you telephone someone who does not live with 
you? 3. How often do you do something with a friend that you have planned ahead of 
time? 
Quality of life was measured by Lehman’s Quality of Life Interview (L-QoLI), brief 
version (Lehman et al., 1988). The item “Satisfaction with life in general” was used.
Medication: Antipsychotic medication, Defined Daily Dose (DDD), was measured using 
the World Health Organization Collaborating Center for Drugs statistics methodology 
(WHO Collaborating Center for Drug Statistics Methodology, 2008).  
Substance abuse: Drug and alcohol abuse were assessed with AUDIT (Alcohol Use 
Disorders Identification Test) (Saunders et al., 1993) and DUDIT (Drug Use Disorders 
Identification Test) (Berman et al., 2005).  
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Suicidality: Suicidality was assessed by asking the patients at the baseline diagnostic 
interview whether they had experienced any suicidal thoughts, plans or attempts in the 
preceding month (suicidality at baseline), or whether they had experienced any suicidal 
thoughts, plans or attempts earlier in their lifetime (suicidality before baseline). The 
questions were repeated in the follow up interviews and suicidal thoughts, plans and 
attempts since last follow up were recorded. Completed suicides were recorded at follow-
up assessments.
Symptom remission: Symptom remission at five year follow-up was defined as a period 
of at least one week without positive psychotic symptoms corresponding to a PANSS 
score >3 on positive subscale items 1, 3, 5 and 6 and on general subscale 9. Time to 
remission was defined as the time from when adequate treatment was initiated to 
remission of symptoms as described above.
Symptom remission criteria were changed at the ten year follow up to comply with the 
international standardized criteria (Andreasen et al., 2005), and included PANSS scores 
of 3 or less on items P1. Delusions, G9. Unusual thoughts, P3. Hallucinatory behaviour,
P2. Conceptual disorganization, G5. Mannerism/posturing, N1. Blunted affect, N4. 
Passive/apathetic social withdrawal and N6. Lack of spontaneity and flow of 
conversation for at least six months. Recovery was also reported at ten years follow up 
and was operationalized as a combination of symptom remission and three functional 
dimensions based on the SCLFS: Day-to-day living (independent living), Role 
functioning (work, academic, or full-time home-making) and Social Interaction. A score 
of 0 indicated very poor functioning, and a score of 4 indicated good functioning. 
Patients in recovery had, during the previous 12 months, fulfilled the symptom remission 
criteria above and scored four on all three functional dimensions.
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Most of the above test-battery was used at baseline and repeated at one, two, five and ten 
years. DUP and PAS were only assessed at baseline, at three months only PANSS and 
GAF were used, and at ten years AES and CDSS were added to the test battery.
Information was collected by interviewing patients, and gathering information from 
family, school and social workers when available. Information was cross checked with 
the medical charts.
Table 1. Instruments specific to individual studies
Paper I Paper II Paper III
PANSS items P1 (delusion) and P3 
(hallucination)
AES-S-Apathy (Clinical apathy) PANSS item N1 (flat affect)
PANSS items G12 (insight) PANSS item N2 (emotional withdrawal)
and N4 (Passive/apathetic social 
withdrawal) =proxy measures of apathy)
Objective social functioning (L-QoLI)
Suicidality (thoughts, plans or 
attempts)
Subjective quality of life (L-QoLI) Symptom remission
Time to remission Calgary Depression Scale for 
Schizophrenia (CDSS)
Recovery
Alcohol and substance abuse (AUDIT 
and DUDIT)
3.4.2 Reliability testing of the main instruments
Assessments at ten years were conducted by one psychiatrist, one clinical psychologist, 
and one psychiatric resident. The raters were trained in using the study instruments by 
rating previously prepared case notes and audiotapes/videotapes before entering the 
study. Good reliability for major variables (GAF, DUP and diagnosis) has been 
documented for earlier raters (Friis et al., 2003). During the early phase of the ten year 
data collection the site coordinators videotaped two PANSS interviews that were rated by 
all three site coordinators. The Intraclass Correlation Coefficients (ICC) two way mixed 
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model was used, as the three raters made all the evaluations. We used the absolute 
agreement option, as this is sensitive to systematic differences between raters. For the 
five PANSS components the ICC ranged from 0.61 to 0.82 with a median of 0.67.
Twenty eight patients gave informed consent for video-recording of PANSS interviews 
for reliability testing. Based on the interviews the GAFs/GAFf measure was also tested. 
The videotaped patients were not significantly different to those who were not 
videotaped on any of the PANSS subscales, or on GAFs/GAFf. Two tapes could not be 
rated due to technical problems. The remaining 26 interviews were rated by an 
experienced psychologist who was not involved in the project and was blind to all 
ratings. The ICC two way mixed model was used, with the consistency option as 
consistency between the site scores and the independent rate’s scores was the point of 
interest. For the five PANSS components the ICCs ranged from 0.61 to 0.82 with a 
median of 0.67. See table below for further details.
Variable ICC 95% CI
PANSS total sum 0.90 0.80 - 0.96
Positive component 0.87 0.72 - 0.94
Negative component 0.81 0.61 - 0.91
Cognitive component 0.82 0.63 - 0.91
Depressive component 0.74 0.50 - 0.88
Excitative component 0.66 0.37 - 0.83
GAF symptoms 0.83 0.65 - 0.92
GAF function 0.88 3.3 - 0.94
3.4.3 Assessment of hallucinations and delusions
In paper I PANSS items P1, delusions, and P3, hallucinations, were used to identify the 
two mono-symptomatic groups. Having hallucinations or delusions was defined as a 
score of  .
The hallucinations only group (H): This group experienced hallucinations (rated as 
3$166VFRUHLWHP3KDOOXFLQDWLRQVRIEXWQRWGHOXVLRQV3$166VFore P1, 
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GHOXVLRQVRI Patients who were found to experience delusions (PANSS score P1, 
GHOXVLRQVRIRQIROORZXSLQWHUYLHZVXSWRDQGLQFOXGLQJILYH\HDUVZHUHUHPRYHG
from the group.
The delusions only group (D): This group experienced delusions (rated as PANSS score 
LWHP3GHOXVLRQVRIEXWQRWKDOOucinations (PANSS score P3KDOOXFLQDWLRQVRI
3). Patients who were found to experience hallucinations (PANSS score P3, 
KDOOXFLQDWLRQVRIRQIROORZXSLQWHUYLHZVXSWRDQGLQFOXGLQJILYH\HDUVZHUe
removed from the group.
3.4.4 Assessment of apathy
In paper II apathy was assessed using the abridged self-report Apathy Evaluation Scale 
(AES-S-Apathy). The Apathy Evaluation Scales has three versions; a clinician rated 
(AES-C), an informant rated (AES-I) and a self-rated (AES-S) version. The scales have 
been translated to Norwegian (Andersson et al., 1999). In this thesis we used an abridged 
version of the AES-S, the AES-S-Apathy. This version has been found to have better 
psychometric properties compared to the 18 item non-abridged version (Faerden et al., 
2008). It consists of 12 questions that are answered on a Likert scale ranging from 1 to 4 
(1=not at all, 4=very much). Patients with scores of 27 or above were considered to be
clinically apathic. This score was two standard deviations (2SD=8.6) above the mean 
sum scores (mean=18.0+/-4.3) of a healthy control group in a study of the AES 
assessment tool in a FEP sample (Faerden et al., 2008). Examples of items in the AES 
are “Getting things done is important to me”, “I spend time doing things that interest 
me”, and “Someone has to tell me what to do each day”. The clinician version of this 
instrument (AES-C-Apathy) has been found to assess apathy in a FEP sample with 
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reliability (Faerden et al., 2008). Good internal consistency was found for AES-S-Apathy 
in the present study (CronbDFK¶VĮ=.89).
3.4.5 Assessment of flat affect
In paper III the PANSS negative component item N1 was used to assess and follow the 
development of FA. Only patients who participated at the ten year follow-up were 
described in this paper (N=186). Two patients were excluded as they lacked more than 
two assessments. For patients who lacked two or less scores a mean score was calculated. 
This score was calculated from the score immediately preceding and following the 
missing score of the patient concerned. We used a PANSS score of 3 as threshold for 
clinically significant FA. A score of 3 is described as changes in facial expression and 
communicative gestures that seems to be stilted, forced artificial or lacking in modulation 
(Kay et al., 1987).  Patients were grouped according to FA symptom trajectory:
1. Never-present (itHPVFRUHRQDOODVVHVVPHQWV
,PSURYLQJVWDUWVHQGV
3. Deteriorating (starts 2, ends 3).
4. Fluctuating (2 fluctuations across threshold for FA).
5. EQGXULQJLWHPVFRUHVRQDOODVVHVVPHQWVDVHSDUDWHVFRUHRIEXWQRWDOORZHG
Reliability testing of the single item flat affect measure (PANSS item N1) at the ten year 
follow-up came out favorably (ICC= .76.).
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3.5 Statistics
The analysis was performed with the SPSS Statistical Program (version 16: SPSS Inc., 
Chicago, IL, USA). Analyses were performed with a significance level of <0.05 and a 
confidence level of 95%. Mean and standard deviations are reported for continuous 
variables and percentages for categorical variables. DUP had a markedly left skewed 
distribution and was transformed to its natural logarithm (lnDUP + 1) which is normally 
distributed, before t-test was performed.
The symptom profile groups in the three papers were compared using conventional 
descriptive methods and t-tests. For non-parametric data, and data of skewed distribution,
Chi-Square and Mann-Whitney tests were performed. In situations where one or more 
expected cell frequencies were below 5, Fisher's exact test was used. When comparing 
more than two groups one way ANOVA was used for parametric data (including the 
Tukey post hoc test). For non-parametric and unevenly distributed data the Kruskal-
Wallis test was used.  
In paper II correlations between baseline variables, clinical and functional characteristics 
and AES-S-Apathy, GAF-F, and s-QoL were calculated as Pearson’s product moment 
coefficients. A general linear model with repeated measurement was used to test the 
longitudinal development of the proxy score for apathy (mean score of PANSS items N2 
and N4).  
To examine whether apathy explained an independent amount of the variance in 
functioning and subjective quality of life adjusting for other important variables, a 
blockwise multiple hierarchical regression analysis was performed. Baseline variables 
were entered into the first and second blocks, AUDIT/DUDIT in the third, PANSS 
positive, cognitive and excitative components in the fourth (PANSS negative component 
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was excluded to avoid problems with colinearity), and CDSS in the fifth block. In the 
sixth block, AES-S-Apathy was entered. By entering apathy last, we could examine if 
apathy explained an additional amount of the variance in functioning and quality of life 
even when controlling for other important variables. 
In paper III binary logistic regression was performed to assess possible baseline 
predictors of enduring flat FA. The model contained three independent variables: 1. 
PANSS baseline positive, depressive, cognitive and excitative components, 2. Baseline 
GAF-F, 3. PAS last social function. The variables were chosen as the FA groups showed 
statistically significant differences on these measures at baseline. Independent sample t-
test was used to compare the enduring group to the other groups on objective social 
functioning from baseline to the ten year follow-up.
3.6 Ethics
The TIPS study was approved by the Regional Committee for Medical Research Ethics 
Health Region II (# S-95189), the Regional Committee for Medical Research Ethics 
Health Region East (# 1.2007.2177) and the Data Inspectorate (Licence # 96/3017-2 and 
# 2003/2052). Biological data collection approved by Norwegian Directory of Health 
(#200403453 and the Regional Committee for Medical Research Ethics Health Region
East (# 493-03-01179).  The Regional Committee for Science Ethics region Sjælland,
Denmark (#1-01-83-0002-07).
Written informed consent was obtained from all participants included in the study. Only 
patients that could understand the study protocol and were able to give informed consent 
were included in the study. Participants were informed of their right to withdraw from the 
study at any time during baseline assessment and throughout the follow-up period. 
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Written informed consent was renewed at five year follow-up. Only patients who had 
agreed to participate in the ten year follow-up were contacted directly. Patients who had 
not participated at the previous follow-up interview but had given earlier consent were 
contacted through mail. The remaining patients (refuser group) were not contacted for 
follow-up interview.
Results from the TIPS study was made available to patients and the public through a 
website run from the Rogaland site; www.tips-info.com. The website includes links to 
articles printed in national and international journals.
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4. Results and summary of papers
4.1 Paper I
Objective: Hallucinations and delusions are often described together, but are known to 
occur separately, and may have different relations to outcome variables. The aim of this 
study was twofold: 1) to identify subgroups of patients characterized by having 
hallucinations only or delusions only during a five year follow-up period, and 2) to 
examine if these groups differed with regard to demographic characteristics, clinical 
characteristics and outcome factors, including suicidality. 
Methods: From the 301 FEP patients included at baseline, individuals with delusions 
only (D) and hallucinations only (H) were identified based on PANSS items P1 
(delusions) and P3 (hallucinations) scores at baseline and through four follow-up
interviews over five years. The subgroups were compared with regards to demographic 
data, diagnosis, premorbid functioning (PAS), duration of untreated psychosis (DUP), 
time to remission (TTR), clinical variables (PANSS components, PANSS G12 insight) , 
global functioning (GAF), suicidality (thoughts, plans and attempts) and completed 
suicides.
Results: Two mono-symptomatic groups of patients were identified, the H (n=16) and 
the D (n=106) group. 179 patients experienced both hallucinations and delusions (dual-
symptom group). The mono-symptomatic groups differed on several baseline variables,
and also with regard to outcome. The H group was significantly younger, had longer 
DUP, and poorer premorbid function. The H group also scored better on the cognitive 
component (statistically significant at two and five years) and, importantly, had better 
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insight at all time points (statistically significant at baseline and five years). Notably, the 
H group scored higher on measures of suicidality. Suicidality before admission was 
significantly higher in the H than the D group. At the five year interview four patients 
from the H group were dead (three from suicide, one from overdose), while in the five 
times larger D group, five patients were dead (two from suicide, one from overdose and 
two from unclear cause). Analyses showed a significantly higher rate of completed 
suicides in the H group (Fisher exact test; p=0.016).
Conclusion: Patients with hallucinations only can be separated from patients with 
delusions only. The subgroups differed with regards to demographical data, clinical 
variables, and most notably with regards to insight and suicidality. These findings 
suggest distinctions in the underlying biological and psychological processes involved in 
hallucinations and in delusions, and alert us to a vulnerable patient group with a clinical 
picture dominated by hallucinations which has received little attention in the earlier 
literature.
4.2 Paper II
Objective: Studies have shown that apathy is an important part of the negative 
symptomatology in psychotic disorders. It is a common symptom early in the course of 
illness, and has been associated with poor general functioning. The aim of this study was 
twofold:1) to examine the prevalence and predictors of self-reported apathy at ten years,
and to assess the development of apathy, using a proxy-measure, prior to the ten year 
follow-up, 2) to explore the relationship between apathy at ten years and concurrent 
symptoms, functioning and outcome, with a particular focus on subjective quality of life.
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Methods: Of the 301 FEP included at baseline, 186 participated in the ten year follow-
up. Of these, 178 patients completed the Apathy Evaluation Scale (AES-S-Apathy). 
Patients were classified as having apathy (AES-S-Apathy27) or not at ten year follow-
up. A proxy measure of apathy (PANSS items N2+N4) was used to assess apathy at 
assessments prior to the ten year follow-up. The relationship between apathy and baseline 
variables (Demographics, Diagnosis, DUP), measures of symptomatology (PANSS,
Calgary Depression Scale for Schizophrenia), functioning (GAF, Strauss Carpenter Level 
of Functioning Scale) and subjective quality of life (Lehman’s Quality of Life Interview) 
were estimated through correlation analyses and blockwise multiple hierarchical 
regression analysis.
Results: Nearly 30% of patients were clinically apathetic at ten year follow-up. No 
baseline measure was found to significantly predict apathy at ten years. Self-rated apathy 
was associated with all measures of psychopathology, as well as with poorer general 
functioning, less contact with friends, and lower level of employment. Proxy measures of 
apathy indicated that the level of apathy declined over the follow-up period. Apathy was 
found to contribute independently to global functioning. Notably, apathy was found to 
independently explain more than 10 % of the variance in subjective quality of life, even 
when other significant correlates were controlled for.
Conclusions: Apathy at ten years follow-up was associated with higher levels of 
psychopathology, poorer general functioning, and poorer subjective quality of life. Even 
though apathy was a common symptom at ten years, the levels appeared to be declining 
during the ten years follow-up period. The finding that apathy was independently related 
to both functioning and subjective quality of life at ten year follow-up confirms apathy as 
a core component of the negative symptom construct. Apathy could thus prove to be an 
important target symptom of rehabilitation programs for patients with psychotic illness. 
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4.3 Paper III
Objective: Flat affect (FA) has been described as enduring, but long term follow-up
studies of FEP patients are lacking. The aim of this study was to study the symptom 
development of FA over a ten year follow-up period, with a focus on prevalence, 
predictors and outcome factors including social functioning.
Methods: Different FA trajectories were identified using the PANSS item N1 (FA) in the 
186 patients followed from baseline through five follow-up assessments over ten years. A
FXWRIIRIZDVXVHGWRLGHQWLI\SDWLHQWVZLWKFOLQLFDOO\VLJQLILFDQW)$Patients were 
classified as having never-present, improving, deteriorating, fluctuating, or enduring FA. 
Groups were compared on baseline variables (Diagnosis, PAS, DUP, demographics, 
PANSS components and global functioning (GAF)) and variables at ten year follow-up
(reassessed diagnosis, PANSS components, GAF, remission and recovery), as well as 
social functioning throughout the follow-up period.
Results: Twenty nine percent of patients never displayed FA, 10 % had improving FA,
18 % deteriorating FA, 40% fluctuating FA, and 5 % had enduring FA. The patients with 
enduring, fluctuating and deteriorating FA did poorer on all outcome variables, including 
GAF, employment, and objective social functioning. The deteriorating FA group was 
similar to the best performing never-present group on symptom and functional measures 
at baseline. By ten year follow-up, however, the deteriorating group was the most 
symptom burdened group with regards to positive, depressive and excitative symptoms,
and had functional levels close to those of the poorest functioning enduring FA group. 
The enduring FA group did significantly poorer with regard to social functioning at all 
assessments during the ten year period, and premorbid social function predicted enduring 
FA.
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Conclusions: FA was expressed at some point of time in the majority of FEP patients in 
the ten year follow-up period, and appeared more fluctuant than expected from the 
relevant literature. FA was associated with poorer outcome at ten year follow-up, and 
enduring FA was associated with poorer social functioning both premorbidly, and at all 
points of assessment.
4.4 Comparing papers I-III: supplementary analyses
Papers I, II and III use the same patient sample, therefore some patients who are 
described as having apathy in paper II may also have clinically significant FA as 
described in paper III. Furthermore, patients with apathy or FA may also be a part of
either the H or the D group. The below analyses have not been reported in the papers, but 
are reported in this thesis as a supplement in order to better compare the three papers. 
4.4.1 Comparing the H and D groups with regard to apathy and FA
Seven of the 16 patients with Hallucinations only were assessed at ten year follow-up.
One (14%) out of these seven scored as having clinical apathy, and 3 (42 %) had FA.
Of the delusion only group 64 out of the original 106 participated in the ten year follow-
up. Of these 15 (14%) scored as having clinical apathy, while 18 (28%) scored as having 
FA. As reported in paper I there was no significant difference between the H and the D
group with regard to subjective quality of life or social functioning throughout the 
follow-up period.
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4.4.2 Comparing patients with apathy and flat affect 
Of the 178 patients that filled out the AES-S-Apathy, 84 (47%) had neither apathy nor 
FA at ten year follow-up, while 33 (19%) patients had both symptoms. Twenty (11%) 
patients had apathy but not FA, and 41 (23%) patients had FA, but not apathy.
No statistically significant difference between the patients with and without apathy at ten 
years was found with regard to measures of suicidality at ten years, and no statistically 
significant differences between the FA groups with regard to suicidality or subjective 
quality of life at ten years were found.
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5. Discussion
5.1 Discussion of the main findings
Paper I explores symptoms within the positive symptom component, while paper II and 
III explore symptoms within the negative symptom component. The main findings were:
1. Patients with hallucinations only and delusions only can be identified and differ 
especially with regard to suicidality.
2. Suicidality may be related to insight in the hallucination only group.
3. The findings suggest distinctions in the underlying processes involved in 
hallucinations and delusions.
4. The level of apathy appears to decline in the follow-up period.
5. Apathy is associated with higher levels of psychopathology and poorer functioning.
6. Apathy is independently related to subjective quality of life.
7. Flat affect is more fluctuant than anticipated.
8. Flat affect is associated with poorer social functioning both premorbidly and 
throughout the follow-up period.
9. Prevalence rates, symptom development and associations to outcome measures support 
apathy and flat affect as separate factors.
10. Symptoms within the positive and negative symptom constructs are separate from 
each other in prevalence and in relation to outcome measures.
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5.1.1 Patients with hallucinations only and delusions only can be 
identified and differ especially with regard to suicidality
In paper I we identified two subgroups of FEP patients with a longitudinal symptom 
profile defined by the presence of either delusions or hallucinations. In a sample of 301 
patients we found a smaller group of 16 patients with hallucinations only, while 105
patients had delusions only. The majority of the sample, 179 patients, experienced both 
hallucinations and delusions in the follow-up period. 
We found that the H group were younger and had completed fewer years of education
compared to the D group. These results differ from the results of studies by Mauri and 
colleagues (Mauri et al., 2006, 2008). They found a group of patients with a clinical 
picture dominated by hallucinations. These patients were older at onset of illness and had 
higher academic achievement compared to a schizophrenia patient group. Our findings,
however, are similar to results from a study of non-clinical voice hearers that reported
that this group was younger than a schizophrenia patient group at the age of onset of 
hallucinations (Honig et al., 1998). A likely reason for the difference between our finding 
and the findings of Mauri and colleagues is that while we studied FEP patients, Mauri 
and colleagues studied patients with chronic psychosis.
The most notable finding in this study is the association between symptom profile and 
suicidality. The H group scored as being significantly more suicidal than the D group at 
baseline. Later in the follow-up period the difference between the groups leveled out, 
possibly due to loss of the most suicidal patients in the H group. At five year follow-up
25 % of the H group was deceased. This is in contrast to the D group, where the mortality 
rate was only 5 %.
The high level of suicidality and suicide in the H group may be related to the clinical 
picture itself. Hallucinations tend to be experienced as frightening, intrusive and 
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imperative, and might themselves lead to suicidal thoughts and acts. In a review of 
schizophrenia and suicidality, the association between command hallucinations and 
suicidality was explored (Pompili et al., 2007). The results were conflicting; three out of 
five studies reviewed found that command hallucinations did not correlate significantly 
with suicidal ideation and attempts, and it is plausible that hallucinations in themselves 
are not the sole explanation of the increased suicidality found in our study.
DUP and premorbid function could be potential mediators of suicidality. Earlier studies 
have found that poor premorbid function may be both a risk factor (Clarke et al., 2006,
Bakst et al., 2010), and a protective factor (Opjordsmoen et al., 2009, Melle et al., 2006)
for suicidality. While some studies have found long DUP to be associated with 
suicidality in FEP (Nordentoft et al., 2002, Westermeyer et al., 1999), other studies have 
failed to find this association (Nordentoft et al., 2002, Bertelsen et al., 2007, Preti et al., 
2009). Furthermore, while longer DUP could explain some of the differences in 
suicidality between the groups before baseline, it is less certain how much it might 
contribute to the higher suicide rate in the H group at five year follow-up. Though 
findings have been inconsistent, many studies have found an association between longer 
DUP and higher levels of negative symptoms (Perkins et al., 2005, Schmitz, 2007, Chang 
et al., 2012), and a recent review of suicidality in FEP suggested that high levels of 
negative symptoms at the time of the first psychotic breakthrough and at relapse could be 
a risk factor (Pompili et al., 2011). The H group had higher levels of negative symptoms 
than the D group at the first two assessments, but the differences did not reach statistical 
significance, and the mean level of negative symptoms in the H group was not very high, 
hence a difference in negative symptoms levels is unlikely to be an explanation for the 
difference in suicidality between the groups.
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5.1.2 Suicidality may be related to insight in the hallucination only 
group
The H group had consistently better insight scores than the D group at all points of 
measure. This indicates that insight could be a potential mediator between hallucinations 
and suicidality in this group. Insight is a well documented risk factor for suicidality in 
schizophrenia (Bourgeouis et al., 2004, Crumlish et al., 2005, Barrett et al., 2010, 
Pompili et al., 2011). Mauri and colleagues reported that the patient group described as 
having Hallucinatory Disorder displayed better insight (Mauri et al., 2006). In addition, a
recent study found that patients with hallucinations, but without concurrent delusions,
had better cognitive insight than patients with delusions only (Engh et al., 2010).
We also found that the H group scored consistently better than the D group on the 
cognitive component of the PANSS. Two recent meta-analyses have found that cognitive 
deficits and poor insight may be linked (Aleman et al., 2006, Raffard et al., 2008). 
The patients with both hallucinations and delusions were similar to the D group with 
regard to suicidality and suicide rate. This could imply that it is not hallucinations per se 
that increase suicidality. A possible hypothesis is that, in the absence of delusions, a very 
obvious symptom like hallucinations could result in better insight in patients that have 
the cognitive capacity to interpret hallucinations as pathological and self-originating, and 
therefore the high level of suicidality seen in the H group is secondary to the higher level 
of insight in this group.
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5.1.3 The findings suggest distinctions in the underlying processes 
involved in hallucinations and delusions
The combined findings in paper I support a distinction in the underlying biological and 
psychological processes involved in hallucinations and in delusions. However,
psychological models of delusion and hallucination formation use overlapping concepts, 
such as attribution bias and deficits in self-monitoring, when they describe how delusions 
and hallucinations arise. Larøi and Woodward have suggested that a two-step process is 
implicated in hallucination formation; the first step being an inability to identify self-
generated mental events, and the second step being a misattribution, whereby these self-
generated mental events are misattributed as coming from another (non-self, alien) 
source (Larøi and Woodward, 2007, Larøi 2012). This model may also be used to explain 
how hallucinations and delusions both overlap and exist as separate phenomena. Patients 
who experience hallucinations mono-symptomatically may undergo only the first step of 
the process, i.e. they are unable to identify self-generated events, but they do not 
misattribute the events and attach delusional content to them. Patients with delusions 
only may undergo only the second step of the process, i.e. misattribution. They are able 
to identify a mental event as self-generated, and thus do not experience hallucinations. 
These patients, however, engage the mental processes, including misattribution, involved
in delusion formation, and attach delusional content to external/non self-generated
events. The two-step process of hallucination formation, thus, only occurs in patients 
with both hallucinations and delusions, i.e. in patients that are both unable to identify 
self-generated mental events, and that form delusions around these events.
In the majority of our sample hallucinations and delusions co-occured, but we were also 
able to identify patients who experienced hallucinations and delusions mono-
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symptomatically. In these patients the symptoms had different associations with
demographics, insight, cognition, and suicidality, supporting a degree of difference in 
etiology between the two symptoms.
5.1.4 The level of apathy appears to decline in the follow-up period
In paper II we found that nearly 30 % of the patients showed clinical levels of apathy at 
ten year follow-up. The prevalence rate of apathy is lower than that found at one year 
follow-up in another broad spectrum FEP sample (Faerden et al., 2010). The TIPS study 
managed, through an early detection strategy, to significantly reduce the DUP. Faerden et 
al.’s sample had a more than five times longer median DUP than ours, but as we found 
no relationship between DUP and apathy in our study, it is unlikely that this could 
explain the difference in the mean score between the samples. Another possible 
explanation could be that we used AES-S-Apathy, while Faerden and colleagues used 
AES-C-Apathy. Clarke et al. (2007) found different cut off scores for AES-C and AES-S. 
However, Faerden and colleagues found about the same mean apathy score for the two 
instruments, and when comparing the AES-S-apathy and the AES-C-apathy at baseline 
they found near similar prevalence rates (54% and 53% respectively) (Faerden et al., 
2009a). Furthermore, the proxy-measures of apathy in our sample show a decrease over 
the follow-up period. Even the patients with AES rated apathy at ten years did not show 
an overall increase on proxy measures of apathy in the follow-up period. 
Earlier studies have documented increasing levels of negative symptoms in schizophrenia 
over the course of follow-up (Crow et al., 1980, Fenton and McGlashan, 1991, 1992,
Breier et al., 1991), and possible decreasing brain grey matter volume associated with 
illness progression (Pantelis et al., 2005, Buckley, 2005), supporting the Kraepelinian 
description of a degenerative process manifested by increasing symptoms and reduced 
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function over time. Our proxy data on the development of apathy, and our prevalence 
rate at ten years, seen in combination with Faerden et al.’s prevalence rates at baseline 
and one year, imply that, for the majority of patients with FEP, apathy is a symptom that 
decreases in severity during the ten years after the first psychotic episode. Our results,
therefore, do not support a neurodegenerative disease model.
5.1.5 Apathy is associated with higher levels of psychopathology and 
poorer functioning 
Our study found that apathy at ten year follow-up was associated with higher levels of 
positive, depressive, cognitive and excitative symptoms, poorer general functioning, and 
less social contacts and employment. We found that apathy gave an independent 
contribution to functioning even when controlling for multiple factors including positive 
and depressive symptoms. This finding is in accordance with previous studies both in 
psychotic disorders  (Foussias et al., 2009, Faerden et al., 2010,), and other brain 
disorders (Van Rekum et al, 2005). These findings validate apathy as an important 
symptom within the negative symptom construct, and as a central part of the 
symptomatology that leads to functional loss in psychotic illness. 
This study does not explore how apathy leads to poor functioning. Previous studies have 
found an association between apathy and reduced executive function (Roth et al., 2004, 
Faerden et al., 2009a). There  is evidence that dysfunction in frontal-subcortical circuits, 
especially those linking prefrontal cortex to striatum, might be involved in both apathy 
(Barch and Dowd, 2010) and executive functioning (Eisenberg and Berman, 2010), and
that the same neural correlates are found in schizophrenia and other neuropsychiatric 
disorders (Bonelli and Cummings, 2007). This association might suggest a shared neural 
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substrate, and a bidirectional relationship between apathy and poor executive functioning 
could explain some of the functional loss found in patients with apathy.
5.1.6 Apathy is independently related to subjective quality of life
We found that apathy at ten years, measured by both AES-S-Apathy and PANSS items 
N2 and N4, was significantly related to subjective QoL. This finding was strengthened
by the fact that apathy remained an important independent predictor of QoL even when 
depressive symptomatology was controlled for. As we used the self-report version of the 
AES, our findings suggest that patients with psychotic illnesses realize their lack of 
motivation, and that amotivation, or apathy, causes them to rate their life situation less 
favorably. Apathy, reframed as a symptom that patients actively experience, and that 
causes distress, could prove an important target for rehabilitative treatment programs. 
Talking to patients about how they experience motivational difficulties and the 
consequences of apathy in their daily life may prove an important ingredient in 
rehabilitative treatment of patients with poor functioning.
5.1.7 Flat affect is more fluctuant than anticipated
A surprising finding in paper III is that FA had a much more fluctuant course than 
expected from studies found in the literature which report negative symptoms as more 
stable than positive symptoms (Pougue-Geile and Harrow, 1985, Johnstone et al., 1987, 
Fenton and McGlashan, 1991, McGlashan and Fenton, 1992, Drake et al., 2003), and FA
as more stable than apathy (Malla et al., 2004, Kelley et al., 2009, Galderisi et al., 2012).
Seventy-one percent of the patients had FA at one or more assessments, but only 5 % had 
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enduring FA, and the largest group of patients, 40% of the sample, had a fluctuating
course. 
The low rate of enduring FA contrasts with previous studies, particularly those that 
describe deficit pathology (Kirkpatrick, 2001, Kirkpatrick and Galderisi, 2008), where 
FA is a key symptom. Our results also differ from two other ten year long follow-up
studies that reported that 19-24 % of schizophrenia/schizoaffective patients had enduring 
negative symptoms (Herbener and Harrow, 2001, Makinen et al., 2010). Our sample 
consisted of a broader range of diagnoses, and this could contribute to the low prevalence 
of enduring FA. In contrast to the study by Herbener and Harrow our study followed 
patients from very early in the course of illness. Our study also followed the sample 
closely, with six assessments in the follow up period. A recent longitudinal FEP study of 
three years duration, found enduring negative symptoms in 23.7%  in the last year of the 
follow-up period, but only in 6.5 % of patients in the first year of follow-up (Chang et al., 
2011). Increasing symptom stability over time have been reported for the negative 
symptoms domain in a ten year follow-up study that conducted monthly assessments 
over a ten year period following first hospitalization (Eaton et al., 1995). When, in the 
course of illness, assessments are commenced, and how many assessments are conducted 
in the follow-up period, probably influence results on prevalence, and these differences 
in study design could explain why earlier studies have found a higher prevalence of 
enduring negative symptoms.
We found that somewhat more patients developed FA (deteriorating group) than 
improved from it (improving group) in the follow-up period. Forty-one percent of the 
sample had clinically significant FA at ten year follow-up, and the overall level of FA 
was largely unchanged in the follow-up period. We did not find a reduction in levels of 
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FA like we did for apathy, however, similar to the results on apathy, our results on FA do
not support a degenerative process, as even the patients with enduring FA did not show 
an ongoing deterioration in the follow-up period. The deteriorating FA group could 
represent a part of the sample that developed chronic negative symptoms similar to what 
has been described as deficit psychopathology (Kirkpatrick, 2001, Kirkpatrick and 
Galderisi, 2008). This group differed from patients with deficit psychopathology in that it
included patients with diagnoses other than schizophrenia. The deteriorating group also
had premorbid function similar to the never-present FA group. Furthermore, the level of 
chronicity of FA in this group is debatable as FA seemed to develop in the latter part of 
the follow-up period and did not necessarily present as stable. We did not assess to what 
degree apathy fluctuated in our sample. An earlier study found that FA, measured four 
times over a one year period, had a more stable course compared to apathy (Kelley et al., 
2009). This may imply that apathy fluctuates to an equal or greater extent than FA as 
measured in this study. Consequently our consideration of negative symptoms as chronic 
and enduring may need to be revised.
5.1.8 Flat affect is associated with poorer social functioning 
premorbidly and throughout the follow-up period.
We found a pronounced association between FA and poor objective social functioning, 
particularly in patients with enduring FA. FA may be viewed as an expressive deficit 
with a specific impact on social communication and interaction. A failure to respond to
social stimuli could reduce the likelihood of establishing and maintaining friendships and
other relationships. FA could also reflect poor social cognition. Social cognition is 
defined as the ability to process and apply social information, and is not regarded as a 
73
part of the negative symptom construct (Kirckpatrick et al., 2006). Social cognition
includes the ability to recognize facial expressions of emotion. Impaired performance on 
affect perception tasks is an established finding in patients with schizophrenia, where it 
has been inconsistently associated with negative symptoms (Kohler et al., 2010).
Impaired social cognition has also been reported in affective psychosis (Kohler et al., 
2011), and in FEP patients (Addington et al., 2006). Furthermore, facial expression 
recognition and unfamiliar face matching has been found to be poorer in schizophrenia 
patients with FA compared to patients without FA (Gur et al., 2006). Studies comparing 
patients with and without FA on emotion processing tasks using fMRI have identified 
increased amygdala activity as a neuronal correlate of FA in schizophrenia (Gur et al., 
2007, Lepage et al., 2011). It has been suggested that increased amygdala activation in 
patients with schizophrenia triggers reduced function of the cortical regions necessary for 
the correct identification and labeling of facial expressions (Gur et al., 2007). Such a
failure to respond to, and interpret, verbal and nonverbal stimuli is likely to affect social
abilities and contacts over time. We also found that poor premorbid social function was 
the strongest predictor of enduring FA. A study of home videos of children that later 
developed schizophrenia compared these to videos of their siblings that remained healthy 
(Walker et al., 1993). The videos reveal that the patients who later developed 
schizophrenia had significantly more affective flattening than their siblings, even from a 
very early age. Thus, it may be that the failure to develop adequate social competency is 
associated with a similar failure to develop an ability to send social signals including 
facial expressions and gestures.
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5.1.9 Prevalence rates, symptom development and associations to 
outcome measures support apathy and flat affect as separate factors
We found that apathy and FA differ in prevalence at ten year follow- up. The symptoms 
also seem to develop differently in our sample, as apathy appears to decrease over time, 
while the mean level of FA remains about the same. Our results further indicate that 
apathy and FA have different associations to outcome measures, including functioning. 
We found that apathy had a strong and independent relation to general functioning and to 
subjective quality of life, and that the correlation between apathy and general functioning 
was stronger than that between apathy and social functioning. FA, on the other hand, 
showed a strong relationship to social functioning throughout the follow-up period, but 
not to quality of life. Combined, our results from paper II and paper III support earlier 
factor analyses that report apathy and FA to be separate factors within the negative 
symptom construct (Blanchard and Cohen, 2005, Foussias and Remington, 2010). The 
different association to functioning could possibly be partly explained by the symptoms 
having different neurocognitive correlates. Earlier studies have reported an association 
between apathy and executive functioning (Roth et al., 2004, Faerden et al., 2009,
Konstantakopoulos et al., 2011). Few studies have looked at the relationship between FA 
and neurocognition. A study by Gur et al. found a significant association between FA and
verbal memory (Gur et al., 2006). The study did not adequately examine executive
function. As previously described, a possible association between FA and poor social 
cognition has been reported (Gur et al., 2006), a similar association has not been reported 
between apathy and social cognition. This area requires further exploration, and the 
possibly different neurocognitive correlates of individual negative symptoms ought to be 
mapped out.
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5.1.10 Symptoms within the positive and negative symptom constructs are 
separate from each other in prevalence and in relation to outcome measures
As apathy and FA are factors within the same symptom construct of negative symptoms 
we expect to find patients with overlapping symptom profiles. When comparing patients 
with apathy to patients with FA at ten years we found that more patients had clinically 
significant FA than apathy at ten years and that only a small proportion of the sample had 
overlapping symptoms. These results further supports factor analyses that show apathy 
and FA to be separate factors within the negative symptom construct. The additional 
supplementary analyses and results also support this conclusion as the association 
between apathy and subjective quality of life was not found between FA and subjective
quality of life. Neither apathy nor FA showed an association to suicidality. Earlier 
literature concludes that the positive and negative dimensions are largely independent of 
each other both cross-sectionally and longitudinally (Fenton an McGlashan, 1991, Arndt 
et al., 1995, Bentsen et al., 1996,Blanchard and Cohen, 2006). Supporting this we found 
a low degree of overlap between the mono-symptomatic positive symptom groups with 
regard to apathy and FA. Both groups scored as having half as many patients with apathy 
as the total patient sample, and while the H group scored as having somewhat higher 
prevalence of FA than the D group, the group had similar prevalence to that of the total 
sample.
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5.2 Methodological issues
The TIPS study is a longitudinal study of a large, epidemiological sample. It is one of the 
first studies to follow a FEP sample prospectively, and with several assessments, over a 
ten year follow-up period. The study kept a close focus on developing and maintaining 
the reliability of measurements used. A range of outcome variables were used throughout 
the follow-up period, and new and relevant instruments, like the AES-S-Apathy, were 
added to the battery of instruments. Limitations of the study related to representativity of 
the sample and the reliability and validity of the instruments used are discussed below. 
5.2.1 Representativity of the sample 
The institutions in the four sites included in the study had responsibility for all patients in 
their catchment areas. Consequently our patients sample should be an epidemiological 
one. A total of 874 persons with psychosis-like symptoms underwent screening by the 
study’s assessment teams. Three hundred and ninety-seven fulfilled inclusion criteria. Of
these, 23% refused to participate in the study, leaving a total of 301 participants at 
baseline. The patients who refused to participate had a significantly longer DUP than the 
participants (32 vs. 10 weeks), and the refusal rate increased with increasing DUP (Friis 
et al., 2003). As a result the study sample is to some degree biased towards a shorter 
DUP. However, many studies ignore the question of refusers, and the few who address 
this issue report refusal rates very close to ours for studies that have a comparatively 
shorter duration of follow-up (Bertelsen et al., 2009, Henry et al., 2010). Thus, it is 
reasonable to believe that the TIPS study sample has a high degree of representativity.
The representativity of the sample at ten year follow-up is investigated in drop-out 
analyses (3.3.3). These analyses showed that the patients who dropped out had 
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significantly longer DUP, shorter education, higher rate of alcohol abuse, were more 
likely to be of non-Scandinavian ethnicity and were less likely to be employed in the year 
prior to inclusion. Longer DUP have been associated with higher levels of negative 
symptoms in some, but not all, studies exploring this relationship (Schmitz, 2007, Chang 
et al., 2011). There were, however, no difference between the included and the dropped-
out patients with regard to the negative symptoms score or levels of proxy measures of 
apathy (PANSS N2 and N4) and measures of FA (PANSS N1) at baseline.
5.2.2 Limitations of the assessment instruments
5.2.2.1 The assessment of hallucinations and delusions
Using the PANSS items P1 and P3 to measure delusions and hallucinations respectively,
provided a measure of the individual patients’ symptoms at the different assessment 
points rather than a recording of life time prevalence of hallucinations and delusions. As 
our patient group was assessed from very early on in their illness, and reassessed two
times in the year after inclusion, we have most likely recorded symptoms in the period 
where most patients in the sample were acutely ill. It is, however, possible that patients 
who relapsed later in the follow-up period experienced hallucinations or delusions for the 
first time, but that this was not discovered. It is also possible that patients who dropped 
out during the follow-up period did so because they developed new symptoms, like 
hallucinations and delusions. The small size of the H group makes it particularly 
sensitive to drop-out. However, most patients in this group dropped out after the two year
assessment, and the symptom profile is therefore well described for most patients in this 
group. At two year follow-up 13 out of 16 patients participated. Two of the non-
participants died between the three month and one year follow-up. The third non-
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participant scored three on the PANSS P1 delusion item at the three month follow-up and 
it could be that this patient dropped out because he or she had developed delusions.
Furthermore, the PANSS P3 item does not differentiate between different modalities of 
hallucinations. Auditory hallucinations, however, are estimated to be the more frequently 
occurring hallucinations in schizophrenia (APA, 2000), and it is thus feasible to use the 
PANSS score as a proxy for auditory hallucinations.
5.2.2.2 The assessment of insight
In paper I we used the PANSS G12 item to assess insight. The PANSS G12 item has 
shown good correlations with more specialized insight measures including the Beck 
Cognitive Insight scale, the Birchwood self rating scale, and the Schedule of Assessment 
of Insight-Expanded version (Engh et al., 2007, Jonsdottir et al., 2008). However, a more 
comprehensive insight measure would have improved our study by better describing 
insight in our sample.
5.2.2.3 The assessment of apathy
The abridged self-report version of the apathy evaluation scale (AES-S-apathy) used in 
our study has been used in fewer studies compared to clinician version of AES (AES-C). 
Clarke and colleagues (2007) reported that AES-S had poorer validity than AEC-C for 
evaluation of apathy in dementia. However, in studies of patients with psychotic 
disorders more favorable results have been found (Kiang et al., 2003, Faerden et al., 
2008). Both studies indicate that the AES-S discriminates well between controls and 
patients. Kiang found that the self-rater and clinician rated versions of AES correlated 
strongly (r=.75), while Faerden and colleagues found an inter-correlation between AES-
S-apathy and AES-C-apathy of 0.63, but that the patients sample had about the same 
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mean apathy score, and the same baseline prevalence rate of apathy using the two 
instruments (Faerden et al., 2008).
As the AES-S-apathy was only added to our test battery at the ten year follow-up, we 
used PANSS items N2 and N4 as proxy measures to assess the longitudinal development 
of apathy. In a small sample (N=28) Kiang and colleagues found a non-significant 
correlation between AES-C and PANSS items N2 and N4 of r= 0.27 and 0.02 
respectively (Kiang et al., 2003). However, in a larger sample of FEP patients, Faerden 
and colleagues found the two items to correlate moderately with apathy scores (AES-C-
apathy rated) (N2, r=.62, N4, r=.52). We found a correlation between AES-S and N2 of 
r=.49 and N4 of r=.48. These results indicate that apathy measured by PANSS differs
from apathy measured by the AES. While the PANSS items N2 and N4 assess 
functioning both in relation to social contact and level of activity and grooming/self care, 
the AES taps into patients’ ability to initiate contact and activities and experienced 
interest in being sociable, managing day to day living, hobbies, and learning new things. 
It is likely that the AES measure is more specific and rates apathy as a primary symptom, 
rather than measuring a functional consequence of being ill, as PANSS seem to do. The 
AES seems thus to be less likely to measure apathy secondary to depression, positive 
symptoms or as side-effect of medication.
5.2.2.4 The assessment of flat affect
The main limitation of paper III is the single item measure of flat affect. Single item 
measures are sensitive to poor reliability. A strength of the TIPS study, however, is that 
intense reliability testing has taken place from baseline and throughout the follow-up
period. The assessment of PANSS item N1 (FA) came out favorably with an ICC score 
of .76 at the ten year follow-up.
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Ideally a more sophisticated measure of FA should have been used. At the start of this 
study no validated instrument specifically assessing flat affect existed. However, since 
the start of the TIPS-study promising computerized FA assessment programs have been 
developed (Hamm et al., 2011). These techniques are however still in their infancy, and 
were considered outside the scope of our study.
5.2.2.5 Primary versus secondary negative symptoms 
Primary negative symptoms are symptoms that are part of the disease process itself, 
while secondary negative symptoms arise as a result of depression, side effects of 
antipsychotic medication, or psychotic withdrawal (Carpenter et al., 1988). In
epidemiological studies of patients with schizophrenia primary negative symptoms are 
estimated to be found in 15–20% of the samples (Kirkpatrick et al., 2001).
Pathophysiological differences between primary and secondary negative symptoms have 
been found (Kirkpatrick et al., 2001). Mapping out secondary negative symptoms are of 
clinical importance as secondary symptoms could be treated with anti-depressive 
treatment if caused by depression, or with adjustment of antipsychotic medication if drug 
induced, or representing social withdrawal secondary to paranoid delusions.
Differentiating primary from secondary negative symptoms, however, is not easy, and 
assessment tools like the PANSS were not created to make this differentiation. Previous 
research has, however, found (AES-C rated) apathy to be a primary symptom in FEP 
patients with depression, antipsychotic medication and positive symptoms having low or 
insignificant contributions to the apathy score (Faerden et al., 2009b). Our study on 
apathy found no significant correlation between apathy and DDD, and a low but 
significant correlation between apathy and positive symptoms. The correlation between 
apathy and depression was slightly higher (PANSS depressive component; r =0.38, and
81
CDSS; r=0.40). It could be that the self-rater version of the AES used in our study 
recruits some patients with a clinical picture closer to depression than primary apathy.
However, our correlations between apathy and the PANSS depressive component are
similar to those found by Faerden and colleagues at one year follow-up of a similar FEP 
sample using the clinician version of the AES. Regression analyses, furthermore, 
confirmed that apathy had a significant and independent contribution to quality of life 
and global functioning scores, also when depression was controlled for.
With regard to FA, previous studies imply that this symptom is more primary in nature, 
as studies report that FA is not significantly influenced by positive and depressive 
symptoms (Malla et al., 2002) or medication (Kelley et al., 1999, 2008).
5.2.3 The diagnostic heterogeneity of the sample
Assessing individual symptoms and diagnosis often proves challenging when patients 
initially become ill, both because information about symptoms may be withheld by the 
patient, or because some symptoms only develop later in the disease process. Like many 
FEP studies, the TIPS study included a broad range of psychotic disorders. A broad 
diagnostic inclusion criterium was used as many patients with a non-schizophrenia 
spectrum diagnosis at baseline later convert to a schizophrenia spectrum disorder (Haahr 
et al., 2008). A further reason to include a broad spectrum of psychotic disorders is that 
these disorders share symptomatology, and that even enduring negative symptoms have 
been documented in non-schizophrenia spectrum psychotic disorders (Gerbaldo et al., 
1995a, b, Herbener and Harrow, 2001, 2004, Malla et al., 2004). In the recent debate on 
how to best describe psychotic disorders the shared biological and genetic correlates of 
these disorders have made many question the dichotomous separation of affective and 
82
non-affective psychosis. Some studies of patients with psychotic disorders have found 
that a dimensional approach may be superior to a categorical approach in terms of 
predictive validity (Allardyce et al., 2007, Peralta and Cuesta, 2008), providing a further 
reason to include patients with a broad spectrum of diagnoses in studies of longitudinal 
symptom development. In the three papers included in this thesis the issues of diagnostic 
differences is explored. The papers mainly compare the patient groups with regard to 
having a schizophrenia spectrum diagnosis or not. The first paper compared a 
hallucination only group to a delusion only group, and found no significant difference 
between the two groups with regard to the percentage of patients with a baseline 
schizophrenia spectrum diagnosis. In paper II the relationship between diagnosis at 
baseline and apathy at ten years was non-significant. In paper III there were no 
differences between the five FA groups at baseline, but at ten years the differences 
between the groups were significant. To assess if the inclusion of non-schizophrenia 
spectrum patients had influenced the results, we repeated the analyses on the 
schizophrenia spectrum patients only (N=139). We found little change in group 
distribution, and only very minor differences with regard to baseline variables and 
outcome measures at ten years, compared to analyses of the full sample. 
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5.3 Implications and further research
5.3.1 Clinical implications
5.3.1.1 Specific symptoms, specific needs
The findings in paper I alert us to a patient group with a heightened risk of suicidality. 
Consequently, identifying patients with hallucination only, and paying special attention 
to risk factors of suicidality, like insight, is important. 
Papers II and III supports previous literature describing apathy and FA as separate factors 
within the negative symptom construct, the clinical implication being that the symptoms 
need to be described and assessed separately. The AES may be a useful tool in clinical 
practice. The instrument is quick and easy to use, and appears to tap into motivational 
difficulties experienced by patients that have implications for functioning. Similarly the 
assessment of flat affect is important, and a better, more specific, instrument for 
assessment could aid clinicians in this task.
This thesis shows that negative symptoms appear to be more fluid than anticipated. This 
may imply a greater potential for treatment responsiveness. As the focus of psychosis 
research has turned from positive symptoms to negative and cognitive symptoms,
treatment forms and rehabilitation programs have been modified or created anew to 
target these symptom components. Our finding that patients appear to have some degree 
of insight into their motivational difficulties and that these difficulties are related to 
poorer quality of life makes apathy more accessible as a therapeutic target. In a cognitive 
behavioural treatment setting this implies addressing motivational difficulties directly 
and working to reduce apathy and amotivation through activity scheduling, mastery and 
pleasure recording, as well as breaking goals into sub-goals that are more easily 
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achievable. This strategy may also be useful in cognitive remediation based rehabilitation 
programs and other rehabilitation programs where motivational difficulties are a major 
obstacle for progression.
Paper III alerts us to an apparent association between social function and flat affect. 
Identifying patients with enduring FA and recruiting these patients to treatment programs 
with a particular focus on enhancing social cognition and functioning may prove fruitful. 
FA might even prove a possible treatment target, and exercises to modulate and enhance 
affect display could enhance social proficiency. Furthermore, clinicians should be 
observant of the patients that develop FA over the course of illness, as our findings imply 
that these patients have a poorer prognosis.
5.3.1.2 What does a diagnosis tell us?
A diagnosis of schizophrenia tells us that a patient has been ill for a period longer than 
six months, and that the illness has been affecting their lives and daily functioning. It 
does not, however, give much information with regard to what symptoms the patient is 
experiencing. As clinicians we want to describe our patients and relay information about 
them in a way that can be best and most efficiently used by the treatment team. By 
describing to what extent different symptom groups are present in each patient we can 
give a fuller picture of patients’ illness and the implications of the illness in their daily 
life. However, by only referring to symptom groups, such as positive, negative, cognitive
and affective symptom constructs, we may be missing vital information. Describing 
someone as experiencing positive symptoms does not tell us if the patient is experiencing 
hallucinations or delusions, if these symptoms are co-occuring, or to what degree patients
express insight into the pathological nature of either symptom. Specifying a symptom 
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profile is even more important for negative symptoms, as these symptoms are less clearly 
defined and more difficult to measure. 
The human mind appears to have a preference of categories to dimensions, as categorical
classification systems allow us to more easily describe and recognize similar phenomena 
and relay information. Classifying disorders into diagnostic entities thus has a high utility 
value. The philosopher Carl Hempel, however, observed that although most sciences start 
by categorically classifying their subject matter, categories are often replaced by 
dimensions as more accurate measurements become possible (Hempel, 1961). Uniting 
the categorical and the dimensional approaches may allow us to preserve the utility of the 
diagnostic system while refining the information about the symptoms that any individual 
patients suffer from. The fifth edition of the Diagnostic Statistical Manual, the DSM-V, 
is in the pipeline and efforts are being made to integrate a dimensional approach in this 
version. There are hopes that a combined categorical and dimensional diagnostic system 
could enrich how we describe patients with psychotic disorders, and contribute to both
efficient relaying of information that describes patients’ individual needs, and give an 
estimate of prognosis.
5.3.2 Future research
The focus of this thesis has been to learn more about specific symptoms experienced in 
psychotic disorders through the exploration of longitudinal symptom profiles. More can 
be learned about these symptoms by studying their potential biological correlates. As 
categorically based diagnosis have proven insufficient in the search for genetic and 
endophenotypic correlates, more can possibly be gained through studies of well 
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described patients with similar longitudinal symptom trajectory. Such studies could 
inform us of possible differences in neurocognitive impairment in patients with 
hallucinations only and delusions only, and how these impairments possibly give rise to 
failure of source monitoring and biased processing. Similarly, this strategy could also 
inform us about the possibly different genetic correlates and structural and functional 
cortical and subcortical changes in patients with enduring, or developing, flat affect and 
apathy. 
To conduct such studies we need better tools to describe and measure the symptoms our 
patients experiences. This is particularly important for negative symptoms. An improved 
instrument for the assessment of negative symptoms would include: 1) clear definitions
of the included symptoms, 2) improved delineation between symptoms, 3) the ability to 
separate primary from secondary negative symptoms, and 4) being user friendly and
intuitive both for researchers and clinicians. Two new tools have recently been developed 
for the assessment of negative symptoms, both reporting promising psychometric 
properties (Horan et al., 2011, Kirkpatrick et al., 2011). These tools could help pave way 
for a better understanding of the symptoms within the negative symptom construct. They 
would also allow an examination of how these symptoms are related to each other, to 
symptoms within other domains, and to functioning. 
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6. Conclusions
This thesis aims to explore the symptom development of two positive symptoms,
hallucinations and delusions, and two negative symptoms, apathy and flat affect, 
in a longitudinal perspective. By examining individual symptoms, rather than 
symptom components, we have gained knowledge about patients with symptom 
profiles that previously have received limited attention. This approach has also 
allowed us to learn more about the development of the individual symptoms over 
time, the longitudinal association between symptoms, and between symptoms and 
outcome measures. The main conclusions of this thesis are as follows:
x Subgroups of patients with hallucinations only and with delusions only can be 
identified in a five year follow-up study, and the groups differ on multiple 
variables.  Most importantly, the hallucination only group scored higher on 
measures of suicidality, and insight might be a possible mediator of suicidality in 
this group.  
 
x Both apathy and flat affect are common symptoms ten years after the first 
psychotic episode, affecting 30 % and 41 % respectively. While the overall level 
of apathy (proxy-rated) in our sample decreased over the follow-up period, the 
level of FA appeared to be largely stable or somewhat increased, with less 
patients showing improvement of FA levels, than patients developing the 
symptom. Also, in the majority of patients FA showed a fluctuant course, and 
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only a very small part of the sample had enduring FA. This implies that FA, and 
negative symptoms in general, are less stable and enduring than anticipated.  
 
x Clinical apathy is strongly related to poorer functioning and subjective quality of 
life in patients ten years after the first psychotic episode. FA is also strongly 
related to poorer functional outcome measures, and in particular to objective 
social functioning. The association between FA and poor social functioning was
evident both premorbidly and throughout the ten year follow-up period.
x The combined findings show hallucination, delusions, apathy and flat affect as 
separate from each other. The symptoms differed in prevalence and symptom 
development. Each of these symptoms also had a different relationship to 
outcome measures including suicidality, subjective quality of life and social 
functioning.
x The exploration of mono-symptomatic patients has alerted us to a patient group 
with hallucinations only that appears vulnerable to suicidality. Clinicians should 
be conscious of this symptom profile, which has received little attention in the 
earlier literature. The assessment of both apathy and FA can aid clinicians in 
caring for patients with psychotic illness and can be a useful starting point for 
rehabilitative efforts. Patients with clinical apathy might benefit from 
rehabilitation programs focusing on experienced motivational difficulties, while 
patients with flat affect might benefit from rehabilitation programs that focus on 
improving social cognition.
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